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 The general aim of the thesis is to investigate the population pharmacokinetics (PK) 
of tacrolimus (Tac) (FK506) in the local Asian liver transplant recipients so as to identify 
possible relationships between clinical covariates and population parameter estimates. 
This can be achieved by (A) determining the population PK of Tac in the local Asian 
paediatric liver transplant recipients, which represents a special subpopulation with 
special PK characteristics, and (B) determining the population PK of Tac in the local 
Asian adult and paediatric liver transplant recipients. 
 
 In the first study, the population pharmacokinetics (PK) of intravenous and oral Tac 
was determined in 20 Asian paediatric patients, aged 1-14 years, after liver 
transplantation. Population modeling using the nonlinear mixed effects model 
(NONMEM) program was performed on the population data set, assuming a one-
compartment model with first-order absorption (ka fixed to 4.5 hr 
-1) and elimination.  
 
 The final optimal population models identified the following relationships: CL 
(L/hr) = 1.46  •  [ 1 + 0.339 • ( AGE (yr) – 2.25 ) ]; V (L) = 39.1 •  [ 1 + 4.57 • ( BSA (m2) 
– 0.49 ) ]; F = 0.197 • [ 1 + 0.0887 • ( WT (kg) – 11.4 ) ] and F = 0.197 • [ 1 + 0.0887 • ( 
WT (kg) – 11.4 ) ] • [ 1.61 ], if the total bilirubin ≥ 200 µmol/L. The mean population 
estimates of CL, V and F were 1.46 L/hr, 39.1 L and 0.197, respectively. The interpatient 
variabilities (CV %) in CL, V and F were 33.5 %, 33.0 % and 24.1 %, respectively.   
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 For the second study, the population PK of oral Tac was determined in 31 Asian 
adult and paediatric patients, aged 1-67 years, after liver transplantation.  A one-
compartment PK model with first-order absorption and elimination was used to describe 
the disposition of Tac in these patients.   
 
 The final optimal population model related CL/F to body weight, the level of serum 
creatinine and the level of alkaline phosphatase, and produced the following relationship: 
CL/F (L/hr) = 14.1 + 0.237*[WT (kg)-55] − 0.0801*[CREA (µmol/L)-60] and CL/F 
(L/hr) = 14.1 + 0.237*[WT (kg)-55] − 2.93 − 0.0801*[CREA (µmol/L)-60], if the alkaline 
phosphatase is ≥ 200 U/L. The final optimal population model related V/F to body height 
and the level of haematocrit of the patient, and produced the following relationship: V/F 
(L) = 217 – 7.83*[HCT (L/L)-31.1] + 179*[HT (m)-1.61]. 
 
 The mean population estimates of CL/F and V/F in the Asian adult and paediatric 
liver transplant patients were 14.1 L/hr and 217 L, respectively. Reasonably large 
interindividual variabilities of 65.7 % and 63.8 % were estimated for CL/F and V/F, 
respectively.  
 
 The population models have identified significant relationships in Asian liver 
transplant patients between the PK of Tac and arthropometric characteristics of the 
patients, as well as the clinical conditions of the patients. Using these models, in 
conjunction with Bayesian forecasting, a truly individualized immunosuppressive therapy 
can be developed and applied. 













    





1.1. Transplantation Immunology 
       
1.1.1. Clinical transplantation  
       
Transplantation is the act of transferring cells, organs or tissues from one site or 
individual to another. It provides effective treatment for various end-stage organ diseases 
of the heart, lung, cornea, liver, kidney and bone marrow   
    
As the majority of the transplants is performed between genetically different 
individuals of the same species (allografts), the immunological response of the recipient 
to the antigens from the donor graft, must be considered. The result of this immune 
response, if left unchecked, will lead to the rejection of the transplanted tissue and both 
cellular (or lymphocyte-mediated) and humoral (antibody-mediated) mechanisms are 
involved.                       
 
1.1.2. Clinical characteristics of allograft rejection 
                                                                                 
 Rejection can be defined as graft damage arising from the response of the 
recipient’s immune system to the transplanted organ. It involves cell- and antibody-
mediated organ injury occurring as the result of recognition of allograft as nonself 
(Arakelov and Lakkis, 2000). This process is caterorised into three major types: 
hyperacute, acute, and chronic. 
     





Hyperacute rejection occurs when an abrupt loss of allograft function occurs 
within minutes to hours after circulation is established in the allograft. This process is 
mediated by preexisting antibodies to allogeneic antigens on the vascular endothelial 
cells within the donor organ (Hanto et al., 1987). These antibodies fix complement 
thereby promoting intravascular thrombosis and leading to rapid occlusion of graft 
vasculature and rapid rejection of the graft (Hammond et al., 1993). Donor recipient 
human leukocyte antigen (HLA) and ABO blood-group cross-matching are used to 
prevent hyperacute rejection (Abbas et al., 1994). There is currently no 
immunosuppressive therapy effective in managing hyperacute rejection. Clinical 
symptomatology associated with hyperacute rejection varies depending on allograft type, 
but typically reflects intensive organ failure.  
 
 Acute rejection may occur within days of transplantation in the untreated 
recipient or may appear suddenly months or even years later, when immunosuppression 
has been employed and terminated. It is a combined process in which both cellular and 
humoral tissue injuries play a part (Oluwole et al., 1989). However, cell-mediated 
immunity mediated by T cells is the primary cause of acute rejection in any one patient. It 
is characterized by necrosis of parenchymal cells within the donor organ. Acute rejection 
can be initiated when graft injury produces an up-regulation of adhesion molecules on 
endothelial cell lining blood vessels in the graft (Nair and Morris, 1995). Host T-cell 
receptors bind to these adhesion molecules increasing their transit time through graft 
vessels and promoting their migration into allograft tissue. Subsequently two varieties of 
cells – T lymphocytes and antigen-presenting cells (APCs) – are recruited (Billingham et 
     





al., 1956). The professional APCs are critical to the immune response. They include 
dendritic cells and macrophages that bind antigen and present it to T cells in the form of 
short peptides bound to the major histocompatibility complex (MHC) of APCs 
(Rammensee et al., 1993; Germain, 1994). MHC is one set of the many 
histocompatibility molecules that has a predominant influence on tissue compatibility and 
is by far the most polymorphic (Klein et al., 1993). The gene products of the MHC 
molecules in humans are called human leukocyte antigen (HLA). There are two main 
types of MHC molecules that are important for allograft transplantation: class I and II. 
The HLA class I molecules are present on all nucleated cell surface to display antigenic 
peptides to the cytotoxic cells (Harris and Gill, 1986). In contrast class II molecules are 
found almost exclusively on cells associated with the immune system: the professional 
APC found in lymphoid tissues and activated T cells (Daor et al., 1984). 
 
Macrophage and polymorphonuclear leukocyte activity dominates the early phase 
of tissue injury. Macrophages produce cytotoxic mediators such as interleukin-1 (IL-1) 
and tumour necrosis factor (TNF) upon recognition of pathogens or foreign antigens. 
These cytokines function to increase recruitment of of T-cells to the graft site. The 
activation of T-cells is the primary factor associated with acute rejection (Gowans et al., 
1962). Activated T-cells also secrete inflammatory cytokines, which interfere in 
microvascular processes to an extent that vascular insufficiency contributes to endothelial 
cell death. Clinical signs which may be associated with acute rejection include general 
malaise, fatigue, myalgia, low-grade fever and pain or tenderness at the graft site (except 
in heart transplant as surgical denervation processes cannot be completely reversed). 
     





Other symptoms may also be observed, such as hypertension, weight gain, decreased 
urine output and increased serum creatinine in acute kidney rejection.                             
    
 Chronic rejection, or late graft failure, is an irreversible gradual deterioration of 
graft function that occurs in many allografts months to years after transplantation (Häyry  
et al., 1993). It is characterized by intimal thickening and fibrosis leading to luminal 
occlusion of the graft vasculature (Abbas et al., 1994). For example, cardiac allograft 
vasculopathy has been detected angiographically in 44% of heart transplant recipients at 
3 years (Uretsky  et al., 1987). This form of rejection involves a variety of immune-
system components: T cells, cytokines, macrophages, and adhesion molecules (Azuma 
and Tilney, 1994). Both immunologic and nonimmunologic factors appear to be involved 
in the ultimate impairment of organ functions. Acute rejection episodes, inadequately 
treated acute rejection, insufficient long-term immunosuppression therapy, preservation 
injury, lipid abnormalities, and infection have all been associated with chronic rejection 
(Ventura et al., 1995). 
         
 The immunology of allograft rejection is not yet fully understood. However, the 
increasing insight into the complexities of these host mechanisms holds promise for 
further improvement in knowledge, their attenuation by both chemical and biological 
agents and eventual success in the production of transplant tolerance, which is the long-
term acceptance of the allograft by the recipient. 
 
     





1.1.3. Prevention or reduction of rejection      
           
 Since the vast majority of transplants come from incompatible unrelated donors, 
nonpharmacologic and pharmacologic means of immunosuppression can be given to 
control transplant immunity so that rejection can be prevented or controlled and that the 




 Total lymphoid irradiation (TLI) is considered an alternative immunosuppressive 
therapy for highly sensitised patients who have received prior organ transplantation 
(Slavin et al., 1980). By targeting x-rays to lymphoid tissues, using small fractionated 
doses to minimize side effects, and discontinuing therapy with the appearance of adverse 
effects, TLI has been used successfully in renal transplant patients in combination with 
low doses of immunosuppressive drugs (Saper et al., 1988). 
 
 In some cases, prior intravenous exposure to donor antigens (especially by blood 
transfusions) can cause prolonged or indefinite graft survival, even though one might 
expect hyperacute graft rejection to occur. This phenomenon is called “active 
enhancement of graft survival.” Active enhancement of graft survival has been employed 




     





 Pharmacologic agents currently provide the primary means of 
immunosuppression after transplantation. Over the past 40 years, compounds that block 
distinct aspects of the immune response have been developed. Immunosuppressive agents 
can be classified according to their mechanisms of action as shown in Table 1.  
 
Mechanism of action Example 
Lymphokine synthesis inhibitors dependent on 
the immunophilin-calcineurin complex 
 
Cyclosporine, Tacrolimus (Tac)  
DNA (nucleotide) synthesis inhibitors 
a. purine antagonists  
b. pyrimidine antagonists 
c. folate antagonists 
d. alkylators 
 
Azathioprine, mycophenolate mofetil 
Brequinar sodium, leflunomide 
Methotrexate 
Cyclophosphamide 








Anti-lymphocyte / endothelial cell biological 
agents 
 
Polyclonal anti-lymphocyte globulin, 
muromonab-CD3 (OKT3), anti-CD4, 
anti-T10, anti-CD52, anti-ICAM-1 
 
Pharmacologic and biologic agents for positive 
and negative selection of bone marrow 
 
Cyclophosphamide analogs, anti-
CD34 monoclonal antibodies 
 
Table 1.  Classification and mechanisms of action of drug and biological agents currently 
used in transplantation. 
 
 Drug combinations hold the greatest promise for managing transplant-related 
immunosuppression. As discussed previously, the allograft rejection process involves 
both T and B cells, multiple cytokines, and inflammatory mediators. Selective drug 
combinations that prevent compensatory immune mechanisms from avoiding suppression 
     





and that take advantage of proven synergism between agents should provide the most 
effective therapy. Drug combinations also allow the use of minimal effective doses of 
immunosuppressive agents so that drug toxicity is diminished.    
  
 The development of immunosuppressive regimens since the mid-1960s has 
resulted in the current use of “triple therapy” or “quadruple therapy” as the standard  
regimen in most transplant centers. Triple therapy, which is low dose cyclosporine or 
Tac, azathioprine, and steroids, takes advantage of the immunosuppressive effects of 
cyclosporine or Tac while minimizing their adverse effects. Quadruple therapy adds anti-
lymphocyte globulin or OKT3 to triple therapy with a delay in the start of cyclosporine 
until adequate renal function is established (Deierhoi et al., 1987). 
 
 Optimal immunosuppressive therapy entails a careful management of the patient, 
which includes proper dosing strategies, measurement of the drug levels in the blood, 
monitoring of graft function using biopsy histology and evaluation of potential side 
effects of the drug. 
 
1.2. Tacrolimus          
  
1.2.1. Discovery and development        
           
 In 1982, workers from Fujisawa Pharmaceuticals (Ibaraki, Japan) started to test a 
wide range of fermented broths from Streptomyces for specific inhibitory effects on 
     





mixed lymphocytes cultures. In 1984, as a result of this screening, strain no. 9993 was 
found to produce a potent immunosuppressant designated by the code number FK506, 
later named Tac (Prograf®). The strain has been designated as Streptomyces tsukubaensis, 
referring to the origin of the soil (Kino et al., 1987). In 1994, Tac was approved for the 
prophylaxis of organ rejection in patients receiving allogeneic liver transplants in the 
United States and later also for use as an immunosuppressant after kidney transplantation.
           
1.2.2. Physicochemical properties  and dosage forms    
                                                                                                                        
 Tac is a neutral, hydrophobic, macrolide lactone with a hemiketal-masked α, β-
diketoamide incorporated in a 23-member ring. Its molecular formula is C44H69NO12 with 
a molecular weight of 804. It appears frequently under its monohydrated configuration. 




3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone,monohydrate. It is 
soluble in methanol, ethanol, propan-2-ol, acetone, ethyl acetate, acetonitrile, methylene 
chloride, chloroform, diethyl ether, sparingly soluble in hexane, petroleum ether and 
insoluble in water (Tanaka et al., 1987).       
 
Tac (Prograf®) is available as 0.5, 1 and 5 mg capsules which is a solid dispersible 
formulation on hydroxypropyl methylcellulose (a water-soluble polymer). In addition, an 
     





intravenous (IV) solution is available as Prograf® Concentrate for Infusion (5 mg/ml) 
containing polyoxyethylene hydrogenated castor oil and dehydrated alcohol. It must be 
diluted in 5 % dextrose or normal saline and administered as a continuous infusion over 
24 hours to minimize the nephrotoxicity of the drug. Ointments containing Tac for the 
topical treatment of skin lesions during autoimmune diseases are under clinical 
development (Alaiti et al., 1998). Tac must not be used with tubing, syringes or other 
equipment containing polyvinyl chloride, since it may be adsorbed on the surface of 
polyvinyl chloride (Taormina et al., 1992), especially at the low dosages used in 
paediatric patients.  
 
Tac is stable for many months at room temperature as a white crystalline powder, 
for at least ten days at room temperature and for almost one year at -70ºC when assayed 
in whole blood (Freeman et al., 1995). It is unstable in alkaline conditions. The UV 
spectrum is unspecific and presents a maximum absorbance at around 205 nm. The 13C 
magnetic resonance spectrum (C2HCl3) reveals that Tac in solution exists as an 
equilibrium mixture of 2 isomers (cis and trans form), probably because of a restricted 
rotation of the amide bond within the macrolide ring.   
 
     


























Figure 1. Chemical structure of Tac (FK506).     
  
1.2.3. Mechanism of action and toxicity        
                                                                                               
 Tac prolongs the survival of the host and transplanted graft in animal transplant 
models of liver, kidney, heart, bone marrow, small bowel and pancreas, lung and trachea, 
skin, cornea, and limb (Hoffman et al., 1990; Yasunami et al., 1990). In animals, Tac 
suppresses some humoral immunity and, to a greater extent, cell-mediated reactions such 
as allograft rejection, delayed type hypersensitivity, collagen-induced arthritis, 
experimental allergic encephalomyelitis and graft versus host disease. 
 
Tac is a relatively specific inhibitor of lymphocyte proliferation and exerts its 
immunosuppressive activity mainly through the following mechanisms. Stimulation of 
     





the T cell by an antigen at the T-cell receptor causes phospholipase-mediated production 
of inositol triphosphate, an increase in cytosolic calcium concentration, formation of an 
activated calmodulin-calcineurin complex, and activation of a competent transcription 
factor (nuclear factor of activated T cells [NF-AT]). Tac binds competitively and with 
high affinity to a 12 k-Da cytosolic receptor (immunophilin) termed as the FK binding 
protein (FKBP-12) (Siekierka et al., 1989). Studies have shown that FK506 elicits its 
immunosuppressive activity by inhibiting the cis-trans peptidyl-prolyl isomerase (PPIase) 
activity of FKBP. The FK506-FKBP complex binds with the catalytic A subunit of 
calcineurin and in turn inhibits protein phosphatase activity of calcineurin. This prevents 
dephosphorylation of the cytoplasmic subunit of NF-AT, which otherwise enters the 
nucleus and activates expression of T cell activation lymphokine genes (Defranco, 1991; 
Flanagan et al., 1991; Liu et al., 1991; Schreiber and Crabtree, 1992). The net result is 
the inhibition of T-lymphocyte activation (i.e., immunosuppression).   
  
The use of Tac as an immunosuppressant is mainly limited by its tolerability 
profile (Winkler and Christians, 1995). Two types of adverse effects must be 
differentiated: those caused by over immunosuppression and those caused by drug 
toxicity. Over immunosuppression results in an increased incidence of infectious 
complications and malignancies, mainly lymphoma, as well as the failure of vaccination. 
All these are nonspecific effects, and their incidence correlates with immunosuppressive 
activity and duration rather than with a specific immunosuppressive drug regimen 
(Plosker and Foster, 2000).          
     
     





   
 Figure 2. Tac mechanism of action (Fujisawa Healthcare Inc Product Monograph, 
2002)  
       
          
The principal adverse reactions of Tac in major clinical trials are neurotoxicity, 
diarrhea, hypertension, nausea, and renal dysfunction. These occur with oral and IV 
administrations of Tac and may respond to a reduction in dosing. The nephrotoxic effect 
of Tac is not due to a decrease in glomerular filtration rate and renal blood flow but 
increased renal vascular resistance caused by Tac. The nephrotoxicity may be related to 
an increased production of thromboxane A2 production in the renal parenchyma (Yamada 
et al., 1992).           
         
Diarrhoea was sometimes associated with other gastrointestinal complaints such 
as nausea and vomiting. Hyperkalemia and hypomagnesemia have occurred in patients 
     





receiving Tac therapy. Tac also has a diabetogenic effect probably due to a change in the 
islet cells’ response to hyperglycemia and a change in peripheral sensitivity of insulin. 
Some patients may require insulin therapy to overcome the hyperglycemic effect of Tac. 
           
 The incidence of major neurological side effect is low (5 %) with Tac and most of 
them occur during the first month following liver transplant (Eidelman et al., 1991). 
According to the Pittsburgh study, the patterns and timing of opportunistic infections 
after surgery are similar under Tac and cyclosporine therapy, occurring early in the post 
transplant stage (Alessiani et al., 1991).  
        
1.2.4. Analytical methods         
           
 Tac concentrations in biological fluids have been measured using a number of 
methods. The currently available assays can be broadly classified as enzyme 
immunoassays, chromatographic/mass spectrometric (MS) assays, a radioreceptor assay 
and bioassay. The analytical methods used for assaying Tac have been reviewed (Alak, 
1997). The methods developed for measurement of Tac are summarized in Table 2. 
            
The development of a simple, specific and sensitive assay method for measuring 
Tac in biological fluids is limited by: the low absorptivity, the low concentration in 
plasma/blood, and the presence of several other drugs in the blood samples obtained from 
transplant patients, which potentially interfere with the analysis of Tac.
     
                     
Table 2. Assays for the quantification of Tac and its metabolites in blood and plasma. 
Assay Matrix Sensitivity CV 
(ng/ml) (%) 




Elisa SPE (Fujisawa) 










(Tamura et al., 1987) 
(Wallemacq et al., 1993) 
(Jusko and D'Ambrosio, 1991) 
Elisa Pro-Trac (IncStar) 









(D'Ambrosio et al., 1994) 
(MacFarlane et al., 1996) 
MEIA Tac (Abbott) 









(Grenier et al., 1991) 













< 5  
< 5 
0.5               
  
(Perotti et al., 1994) 
(Takada et al., 1990) 
(Beysens et al., 1994) 





    
< 5 (Friob et al., 1991) 











(Christians et al., 1991) 
(Taylor et al., 1996) 
T cell inhibition Plasma 0.1 NA > 72 (Zeevi et al., 1991) 
Radioreceptor assay Blood 1 8.2-9.2 3-5 (Murthy  et al., 1992) 
Pentamer formation assay Blood 2 5.7-13.7 3-5 (Armstrong et al., 1998) 
Functional reporter gene 
assay 
 
Blood 0.5 5.4 -12.7 8 (Taupin et al., 2001) 
 
CV = coefficient of variation; ELISA = enzyme-linked immunosorbent assay; HPLC = high pressure liquid chromatography; LPE = liquid phase extraction; 
MEIA = microparticle enzyme- linked immunoassay; MS =mass spectrometry; NA = not applicable; SPE = solid phase extraction.
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1.2.5. Pharmacokinetics 
             
Tac is primarily used in transplant patients who receive an organ that is either 
involved in the absorption (small bowel) or elimination (liver) of the drug. The physiological 
status of the organs transplanted is expected to influence the absorption, distribution and 
metabolism of Tac (Venkataramanan et al., 1995). Time-dependent changes in the 
absorption, distribution and metabolism of Tac are also anticipated in patients receiving Tac 
therapy. Tac activity is primarily due to the parent drug (Venkataramanan et al., 1995). 
  
 Absorption   
Tac is absorbed rapidly in most patients, with peak plasma/blood concentrations 
being reached in about 0.5 to 1 hour, while in other patients the drug is absorbed slowly over 
a prolonged period, yielding essentially a flat absorption profile (Gruber et al., 1994). A lag 
time of 0 to 2 hours has also been reported in some liver transplant recipients (Jusko et al., 
1995a). The oral F (bioavailability) of Tac is poor and ranges from 4 to 89 % (mean around 
25 %) in kidney and liver transplant recipients and in patients with renal impairment (Gruber 




 Because Tac is a substrate of the cytochrome P450 (CYP) 3A4 isoenzyme (Sattler et 
al., 1992), its poor F is most likely caused by presystemic metabolism in the gut wall and 
liver. Several studies have shown that Tac is also a substrate of permeability-glycoprotein (P-
glycoprotein) efflux pump, the 170-kd product of the human multidrug-resistance 1 (MDR-1) 
gene, a member of the adenosine triphosphate binding cassette superfamily of active 
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transporters (Wacher et al., 1995), that is found at the luminal face of enterocytes and that 
has also been shown to play a role in intestinal absorption mechanisms (Lo and Burckart, 
1999). It is, therefore, very likely that the poor and variable F of Tac is at least partly caused 
by the activity of this efflux pump in the intestine and genetic polymorphism of the P-
glycoprotein (Hoffmeyer et al., 2000). 
 
 The rate and extent of Tac absorption were greatest under fasted conditions. The 
presence and composition of food decreased both the rate and extent of Tac absorption 
(Bekersky  et al., 2001). Efforts to increase the oral F of Tac and to reduce its variability 
include the synthesis of Tac prodrugs (Hiroshi et al., 1999), the development of oral 
formulations based on liposomes (Lee et al., 1995) and emulsions (Uno et al., 1997). 
 
Distribution and protein binding 
 Tac is highly lipophilic and undergoes extensive tissue distribution, as evidenced by a 
large volume of distribution at steady state (VSS ~ 1300 L) estimated from plasma data 
(Peters et al., 1993). However, VSS estimated from whole blood data was very small (~ 48 L), 
indicating that there is extensive partitioning into red blood cells. In blood, erythrocytes 
sequester 75-80 % of the Tac as it has a high affinity for the FK-binding proteins and the 
abundance of these proteins in erythrocytes and lymphocytes (Nagase et al., 1994). This 
results in whole blood concentrations of Tac being substantially higher than plasma 
concentrations. The distribution of Tac between whole blood and plasma depends on several 
factors, such as hematocrit, temperature at the time of plasma separation, drug concentration, 
and plasma protein concentration. In plasma, more than 98.8 % of Tac is bound to plasma 
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proteins, mainly albumin, α1-acid glycoprotein, lipoproteins and globulins (Nagase et al., 
1994). In animal studies, Tac is widely distributed into tissues with the highest accumulation 
in lung, spleen, kidney, heart, pancreas, brain, muscle and liver (Wijnen et al., 1991).   
      
Metabolism  
Tac undergoes extensive hepatic metabolism with < 1 % of unchanged drug being 
excreted in the bile, urine and faeces after intravenous or oral dosing. Metabolism is mainly 
by the CYP P450 3A enzyme system (Sattler et al., 1992) and CYP enzymes other than P450 
3A have a minor involvement. Tac undergoes O-demethylation, hydroxylation and/or 
oxidative metabolic reactions. Several metabolites are the product of a two-step reaction: 
oxidation by CYP enzyme destabilizes the macrolide ring and leads to its rearrangement 
(Lhoëst et al., 1993). Seven different isomers of 13-O-desmethyl-Tac were detected by using 
2-dimensional homo- and heteronuclear magnetic resonance experiments in one study 
(Schüler et al., 1993).  
            
 The role of phase II metabolism in Tac elimination is unclear. It was speculated that 
early eluting peaks in liquid chromatography after incubation of Tac with rat and human liver 
slices may represent secondary or conjugated Tac metabolites (Ueda et al., 1996). In liver 
transplant recipients, the demethylated and didemethylated metabolites were found primarily 
in the blood and urine, while the hydroxylated metabolites were prominent in the bile 
(Christians et al., 1991). The Tac metabolites, except for 31-O-desmethyl Tac, which in vitro 
exhibits immunosuppressive activity comparable to that of tacrolimus, have negligible 
immunosuppressive activity (Tamura et al., 1994). Since 31-O-desmethyl Tac is only a 
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minor metabolite in blood (Mancinelli et al., 2001), it seems reasonable to assume that the 
metabolites do not significantly contribute to the overall immunosuppressive activity of Tac 
(Plosker and Foster, 2000). 
 
Excretion 
In healthy subjects, the total body clearance (CL) based on whole blood 
concentrations was 2.43 L/hr compared with 4.05 L/hr in liver transplant patients and 6.7 
L/hr in kidney transplant patients. The elimination half-life (t½) based on whole blood 
concentrations averaged 17.6 hours in healthy volunteers, 11.7 hours in liver transplant 
patients, and 15.6 hours in kidney transplant patients.       
 
In a mass balance study of IV administered radiolabelled Tac to six healthy 
volunteers, the mean recovery of radiolabel was 77.8 ± 12.7 %. Faecal elimination accounted 
for 92.4 ± 1.0 % and the t½ based on radioactivity was 48.1 ± 15.9 hours whereas it was 43.5 
± 11.1 hours based on Tac concentrations. The total body CL of radiolabel was 37.2 ± 18 
ml/min and that for tacrolimus was 37.5 ± 9.8 ml/min. When administered orally, the mean 
recovery of the radiolabel was 94.9 ± 30.7 %. Faecal elimination accounted for 92.6 ± 30.7 
% and urinary elimination accounted for 2.3 ± 1.1 % (Möller et al., 1999).                                                
 
1.2.6.   Drug interactions          
                                                                                                  
 Drug interactions occur when the efficacy or toxicity of a drug is altered by 
coadministration of another drug. The interaction between Tac and other drugs can be 
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divided into three categories: (i) physical interactions; (ii) metabolic interactions; and 
pharmacodynamic interactions.         
  
Physical interactions   
Aluminium hydroxide gel appears to physically adsorb Tac in vitro (Steeves et al., 
1991). This same in vitro study also indicated that Tac concentrations are significantly 
decreased in the presence of magnesium oxide due to a pH-mediated degradation (Steeves et 
al., 1991). Widely variable trough plasma Tac concentrations were observed in patients 
taking sodium bicarbonate temporally close to Tac administration. Coadministration of Tac 
with sodium bicarbonate results in lower blood concentrations of Tac (Venkataraman et al., 
unpublished observations). Separation of the administration of these 2 agents by at least 2 
hours, or the replacement of sodium bicarbonate by sodium citrate and citric acid, results in 
stable trough plasma Tac concentrations in patients.       
    
Metabolic interactions 
Since Tac is metabolized by the CYP450 3A enzyme system, co-administration of 
drugs which inhibit CYP450 3A will decrease the metabolism of Tac with resultant increases 
in whole blood or plasma levels (Mignat, 1997). Co-administration of drugs known to induce 
these enzyme systems may result in an increased metabolism of Tac and decreased whole 
blood or plasma levels. Monitoring of blood levels and appropriate dosage adjustments are 
essential when such drugs are used concomitantly. Table 3 shows some agents, which 
potentially alter the metabolism of Tac.   
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Pharmacodynamic (PD) interactions   
The addition of nephrotoxic drugs such as nonsteroidal anti-inflammatory drugs 
(Sheiner et al., 1994), aminoglycosides (Paterson and Singh, 1997), or amphotericin B 
(Paterson and Singh, 1997) to Tac therapy might result in an increased risk of nephrotoxicity 
in transplant patients and should warrant increased observation of these patients for signs of 
nephrotoxicity. The combined use of cyclosporine and Tac results in synergistic 
immunosuppression and increased nephrotoxicity (McCauley  et al., 1990). 
 
1.2.7. Tac immunosuppressive therapy optimisation      
 
1.2.7.1 Therapeutic drug monitoring 
            
 Therapeutic drug monitoring (TDM) is useful and/or even necessary for dose 
adjustment to avoid toxicity as a result of too high and ineffectiveness as a result of too low 
blood concentrations. This is the case when drugs have one or more of the following PK 
characteristics (Evans et al., 1992):        
  
1)  wide inter- and/or intra-individual variations      
       2)  low correlation between dose and blood concentrations    
       3)  difficult to recognize signs of toxicity      
       4)  influence of pathophysiologic factors on PK      
       5)  drug interactions in combinations with narrow therapeutic indices
    
       
                  
    
Drug    Proposed mechanisms Clinical effect References
Diltiazem Inhibition of CYP3A Increased Tac exposure → toxicity (Hebert and Lam, 1999) 
Mibefradil Inhibition of CYP3A Increased Tac exposure → toxicity (Krahenbuhl et al., 1998) 
Fluconazole Inhibition of CYP3A Increased Tac exposure → toxicity (Osowski et al., 1996) 
Erythromycin Inhibition of CYP3A Increased Tac exposure → toxicity (Padhi et al., 1997) 
Theophylline Inhibition of CYP3A Increased Tac exposure → toxicity (Boubenider et al., 2000) 
Danazol Inhibition of CYP3A Increased Tac exposure → toxicity 
 
(Shapiro et al., 1993) 
Protease inhibitors Inhibition of CYP3A Increased Tac exposure → toxicity (Sheikh et al., 1999) 
Carbamazepine Induction of CYP3A2 Decreased Tac exposure → rejection, 
no clinical report 
 
(Mignat, 1997) 
Rifampicin Induction of CYP3A4 Decreased Tac exposure → rejection (Chenhsu et al., 2000) 
 
Table 3.  Agents that may alter Tac metabolism. 
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Tac meets all these requirements indicating that TDM is mandatory. Issues related to 
TDM of Tac include the appropriateness of whole blood as the matrix in which to measure 
Tac, the stability of Tac in blood or plasma and the therapeutic range of Tac. A consensus 
document on therapeutic monitoring of Tac has defined the therapeutic range, matrix, time of 
sampling, rules for assessing the laboratory performance, and the frequency of TDM (Jusko 
et al., 1995b). The therapeutic ranges of whole blood Tac levels at various periods post liver 
transplant, based on this consensus report is shown in Table 4. 
 
 
Time post-transplant 1 – 4 weeks 
 
1 – 12 months > 12 months 
Tac whole blood trough 
concentration (ng/mL) 
15 – 20 
 
 
8 – 12 5 - 10 
Table 4. Therapeutic ranges of Tac at various periods post liver transplant. 
             
Monitoring of Tac blood concentrations in conjunction with other laboratory and 
clinical parameters is considered an essential aid to patient management for the evaluation of 
rejection, toxicity, dose adjustments, and compliance. Factors influencing frequency of 
monitoring include but are not limited to hepatic or renal dysfunction, the addition or 
discontinuation of potentially interacting drugs and the post-transplant time 
(Venkataramanan et al., 1995). For example, monitoring every 1-2 days is required 
immediately post-transplant due to variable PK and acute infection. For the first 3-6 months, 
2-3 times a week until the patient is stable. Beyond 6 months, once every few months, or 
whenever clinically indicated. In addition, other tests are required to check on the adverse 
effects of immunosuppressants include creatinine for nephrotoxicity, liver function and 
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glucose for possible endocrine changes as indicated by either glucose elevation or 
depression.  
    
Although there is a lack of direct correlation between Tac concentrations and drug 
efficacy, data from Phase II and III studies of liver transplant patients have shown an 
increasing incidence of adverse events with increasing trough blood concentrations 
(Schwartz et al., 1995). In a retrospective analysis of 13,000 blood samples obtained from 
248 liver and kidney transplant patients receiving Tac immunosuppressive therapy, Winkler 
et al. reported that whole blood Tac concentrations correlated with clinical events related to 
organ rejection and toxicity (Winkler et al., 1994). Most patients are stable when trough 
whole blood concentrations are maintained between 5 and 20 ng/mL (Venkataramanan et al., 
1995). Long-term post-transplant patients are often maintained at the low end of this target 
range. In a retrospective analysis of trough whole blood concentrations within a 7-day 
window before the onset of rejection, blood concentrations were well correlated with the 
onset of rejection (Kershner and Fitzsimmons, 1996). 
 
In an investigation to determine the clinical utility of monitoring Tac blood 
concentrations in liver transplant patients involving 111 subjects from 6 transplant centres 
evaluated over 12 weeks post-transplantation, Tac blood concentrations were shown to 
provide information of predictive value for managing the risk of nephrotoxicity, other 
toxicity, and rejection in liver transplant patients (Venkataramanan et al., 2001). In paediatric 
liver transplant patients, rejection was shown to be most frequent at blood concentrations less 
than 10 ng/mL (Yasuhara et al., 1995). In a retrospective PD investigation on 35 paediatric 
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liver recipients who received oral Tac as the primary immunosuppressant, a statistically 
significant relationship exists between some Tac toxicities (nephrotoxicity, neurotoxicity and 
diarrhoea) and tacrolimus trough concentrations (Staatz et al., 2004). To minimize toxicity in 
the later post-transplant period, it was proposed a target trough Tac concentration of 6 ng/mL 
be reached by the authors. 
 
A new strategy for drug optimisation in transplant recipients is represented by dose 
adjustment on the basis of drug target activity. Recent studies have evaluated the effects of 
Tac on calcineurin phosphatase activity in blood (Koefoed-Nielsen et al., 2002). Plasma or 
blood concentrations of Tac did not correlate with degree of calcineurin inhibition, while 
most studies show a wide interpatient variability of drug effects. Although this strategy for 
drug optimisation needs to be further investigated, it may prove effective to improve dose 
optimisation of Tac in individual transplant recipients. 
 
In conclusion, it can be seen that monitoring Tac blood concentrations are useful for 
minimizing the risks of both rejection and toxicity in liver transplant patients. Routine 
monitoring of Tac blood concentrations must be used in conjunction with appropriate clinical 
evaluation of the patient to optimise immunosuppressive therapy.    
  
1.2.7.2 Pharmacogenomics and pharmacogenetics 
 
The advent of the genomic era has brought several new fields of study, including 
pharmacogenomics, which seek to link drug treatment with the individual’s genetic makeup. 
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Thus it represents a new approach to tailor immunosuppressive therapy during organ 
transplantation (Danesi et al., 2000). Pharmacogenomics and the much older science of 
pharmacogenetics examine the genetic factors that contribute to variability in drug response 
in individual patients. Specifically, pharmacogenetics refers to the field science that focuses 
on how single genes modulate the effect of a drug while pharmacogenomics refers to the 
science that focuses on how the genome as a whole affects the action of a drug, referring to 
the contribution of individual genes, as well as to gene-to-gene interactions (Yagil and Yagil, 
2002). 
 
In recent years, much research has focused on the possible causes of the 
interindividual and intraindividual differences in the PK of Tac. It has become clear that the 
biologic activities of the permeability-glycoprotein (P-glycoprotein) and the CYP450 enzyme 
system, especially CYP3A4 and CYP3A5, play an important role in this respect (Shimada et 
al., 1994). Part of the interindividual differences in the PK of Tac have been attributed to 
interindividual heterogeneity in enzymatic activity of P-glycoprotein and CYP3A. However, 
the cause of this heterogeneity in enzymatic activity remains to be elucidated.    
  
Recently, a number of single nucleotide polymorphisms (SNPs), which are common 
variations in the structure of a gene and consist of one-nucleotide alteration in the sequence 
of a gene (McCarthy and Hilfiker, 2000), were described for the MDR-1 (Hoffmeyer et al., 
2000; Kim et al., 2001; Tanabe et al., 2001), CYP3A4 (Rebbeck et al., 1998; Sata et al., 
2000), and CYP3A5 (Jounaidi et al., 1996; Hustert et al., 2001; Kuehl et al., 2001) genes. 
The C3435T mutation in the MDR-1 gene has been associated with decreased protein 
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expression, whereas the CYP3A5*3 and CYP3A5*6 alleles were found to cause alternative 
splicing and protein truncation, resulting in the absence of functional CYP3A5 from liver 
tissue (Hustert et al., 2001; Kuehl et al., 2001). For the CYP3A4*1B allele, an increased 
transcription was demonstrated in vitro, which would theoretically result in higher enzymatic 
activity in vivo (Amirimani et al., 1999). Therefore these genetic polymorphisms may 
provide an explanation for the observed variability in Tac PK. 
 
The polymorphisms associated with the expression of CYP3A5 seem to have a 
greater importance than those of CYP3A4. A study of paediatric heart transplant patients 
(Zheng et al., 2003) demonstrated that the dose requirements for Tac were higher in 
expressors (genotype, CYP3A5 1*/3*) compared with non-expressors (genotype, CYP3A5 
3*/3*) at 3, 6 and 12 months post-transplantation. Macphee et al. (Macphee et al., 2002) 
described similar Tac dose requirement patterns for adult renal transplant patients. The 
authors suggested that the P4503AP1*1 genotype was a major influence in determining Tac 
dose requirements. This polymorphism, at position 44 of the P4503AP1 pseudogene 
(P4503AP1*1 or G-allele) is in linkage disequilibrium with CYP3A5*1. It results in either 
the presence or absence of P4503A5 enzyme (Kuehl et al., 2001; Lin et al., 2002). 
Individuals with a G-allele (P4503AP1*1) express hepatic CYP3A5 enzyme (Kuehl et al., 
2001; Lin et al., 2002), whereas AA homozygotes (P4503AP1*3/*3) do not. Thervet et al. 
reported the significant effect of CYP3A5 genetic polymorphism on Tac dosing requirements 
in renal transplant recipients (Thervet et al., 2003). Their results in a cohort of 80 renal 
transplant recipients show that the *1/*1 variant (5% of the population) required a lower 
mean dose of Tac to achieve trough concentrations of 10 to 15 ng/mL compared with the 
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*3/*3 homozygotes (84% of the population) (0.16 mg/kg/day vs. 0.25 mg/kg/day, P=0.05). 
The *1/*1 genotype was found mostly in black patients, which corresponds with previously 
identified ethnic differences, with African Americans known to require higher doses 
(Andrews et al., 1996). 
 
Several polymorphisms have been found for the MDR-1 gene (Hoffmeyer et al., 
2000; Kim et al., 2001; Tanabe et al., 2001). Of these, three mutant alleles on exons 12, 21 
and 26 correlate with expression of the MDR-1 gene and function of P-glycoprotein. The 
G2677[A/T] SNP was shown to influence blood concentrations of Tac in paediatric heart 
transplant patients (Zheng et al., 2003), but not in liver transplant recipients (Goto et al., 
2002). The C3435T SNP was shown to affect Tac dose requirements in renal transplant 
patients (Macphee et al., 2002). 
 
Thus it can be seen that there is scope for genetic analysis to be used in the clinical 
field at present, with pretransplant testing of genes allowing a more scientific dosing in the 
first few days posttransplant. The initial aim of this should be to identify those patients with 
increased drug requirements to avoid underimmunosuppression. It may also be possible to 
identify groups of patients who are more likely to develop drug-related side effects at 
therapeutic doses. With clearer understanding of the interactions involved, it may be possible 
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1.3 Literature review 
 
A literature review of the PK studies of Tac in adult and paediatric transplant patients 
was conducted and the results summarized in Tables 5 and 6, respectively. From the results, 
it can be seen that there are more PK studies of Tac carried out in adult transplant patients 
than in paediatric patients. Also, most of the studies were conducted in Caucasian patients. 
Thus, there is a need for PK studies to be conducted in the asian paediatric transplant patients 
to provide population mean parameters required for dosage adjustments of Tac 
immunosuppressive therapy in this group of patients. 
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Liver         16 33-35 Caucasian IV
Oral 
0.014 – 0.11 





(Jusko et al., 
1995a) 
Liver         
          
          
           
            
       
           
       






1.52 0.021a (Fukatsu et al., 
2001) 
Liver 9 24-64 Caucasian IV 0.15  17.6±9.4 1.49±1.48 (Jain et al., 
1993) 
Liver 7 20-61 Caucasian Oral 0.08±0.04 17.4±6.4 328±280 (Gonschior et 
al., 1994) 
Renal 18 43±14 Caucasian Oral 0.08±0.07 116±50 (Hardinger et al., 
2004) 
Renal 15 21-56 Caucasian Oral 0.3 43.7(126%) 13.6(69%) 254 (75%) (Higgins et al., 
2000) 










(Tuteja et al., 
2001) 
Renal 22 35.7±10.1 Caucasian
and non-
caucasian 
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(Boswell et al., 
1998) 
Heart 11 >18 Caucasian Oral 0.053±0.031 23.6±22.4  (Undre et al., 
1998) 
Heart 22 36-64 Caucasian Oral 0.3 30.5±13.8  236.3±88.6 (M D Aumente 
Rubio et al., 
2003) 
Heart 14 23-61 Caucasian Oral 0.06-0.8 10.7-84.4 <5-54.1 103.5-728.7 (Regazzi et al., 
1999) 
a Based on an adult recipient with living-donor liver transplantation, with grafted hepatic weight of 600 g and normal hepatic and renal function on post-operative     
day = 30.  
           b Preprandial group 
           c Postprandial group 
 d Based on an adult recipient with 70 kg body weight, total bilirubin < 2 mg/dL, serum creatinine < 2  mg/dL, graft-versus-host disease grade I or II and absence 
of veno-occlusive disease.                                                                                                                                                                                 
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Liver           
          
           
         
         
33 0.25-15 Asian IV/oral 0.06/0.30 19±  
4 
2.76a 0.075b (Yasuhara et al., 
1995) 
Liver 18 0.25-16 Caucasian Oral 0.21 (0.06-
0.44) 
0.21c (Sanchez et al., 
2001) 
Renal 14 5-23 Caucasian Oral 0.16 (0.04-
0.30) 
15.2±6.7 7.1±2.6 104±33 (Filler et al., 
1997) 
























(Mehta et al., 
1999) 
 a  V estimated for 15 kg according to: V (L) = 2.76•(TBW/15)0.29 and TBW is total bodyweight. 
    b  CL estimated for 15 kg and days after operation (POD) = 0 according to CL (L/h) = (0.0749 +  0.000457•POD)•size when size = 2.76•(TBW/15)0.29. 
c  CL estimated for 15 kg according to CL (L/h) = 10.4•(TBW/70)0.75 •e-0.00032 t  • e -0.057 BIL (1-0.079ALT) when time after treatment initiation (t) = 0, bilirubin 
    (BIL) = 0.6 mg/dL and normal alanine aminotransferase (ALT = 0). 
d  CL decreases with time. 
AUC12  = area under the concentration-time curve from 0 to 12 hr; Cmax = maximum drug concentration; Cmin = minimum drug concentration. 
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2. RESEARCH GOAL AND OBJECTIVES 
 
The overall goal of our research is to optimise the use and patient outcomes of Tac 
immunosuppressive therapy in liver transplantation. 
      
The specific objectives are:  
                                                            
(1) To retrospectively determine the population PK of oral and IV Tac in local Asian 
  paediatric liver transplant recipients, which represents a homogeneous  
  subpopulation with special PK characteristics.  
        
(2) To prospectively determine the population PK of oral Tac in the local Asian liver 
transplant recipients, comprising of a more heterogeneous group of paediatric and 
adult patients using a bioanalytical assay to measure blood concentrations of Tac. 
 
For the determination of the population PK of Tac, the data were analyzed with a 
systematic approach to screen covariates for inclusion into the population model and the 
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3.1. Study Aims 
                                                                                                                             
 The PK of Tac have been investigated extensively in adult liver transplant patients 
(Jain et al., 1993; Lee et al., 1993; Mekki and Lee, 1994; Undre and Möller, 1994; Jusko 
et al., 1995a). However, there is limited data on the PK of Tac in paediatric liver 
transplant patients (Yasuhara et al., 1995; Wallemacq et al., 1998). This hampers the 
development of optimal treatment protocols, individualisation of doses and successful 
utilisation of therapeutic drug monitoring in paediatric transplant patients. These could 
affect the clinical outcomes especially since Tac has a narrow therapeutic index, a large 
variation in PK within and between individuals; is subject to a range of metabolic drug 
interactions involving cytochrome P450; and produces adverse effects such as 
nephrotoxicity and neurotoxicity (Venkataramanan et al., 1995). Thus the paucity of age-
specific PK data has caused difficulty in defining the optimum dosage regimen and has 
highlighted the usefulness of TDM.  
              
 The technique of population PK was developed for the interpretation of the limited 
data available from a wide range of patients, rather than the extensive data from few 
subjects generated in typical PK studies (Whiting et al., 1986). By definition, population 
PK is the study of the PK similarities and differences between individuals from 
measurements of drug levels in biological fluids of subjects or patients arising from some 
population of interest (Aarons, 1991).  
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The nonlinear mixed-effects model (NONMEM) population PK program 
(Boeckmann et al., 1992) was used to assess information regarding the PK profile of Tac 
in this fragile population. It allows for the development of a complete population PK 
model, including average PK parameters, covariates and the intra- and inter-individual 
variabilities. Such modeling is especially useful when there are only a few PK 
measurements from each individual sampled in the population, or when the data 
collection design varies considerably between these individuals. Results from a 
population analysis will provide specific subpopulation parameters to be used in 
predictions. This is in contrast to using general population parameters, which may be 
inappropriate to achieve the target whole blood Tac concentration range of 10-20 ng/mL, 
a concentration range that has been found to be therapeutic in paediatric liver transplant 
inpatients after living-related liver transplant (Yasuhara et al., 1995).   
         
 The purpose of this study was to investigate the disposition of Tac in a group of 
sixteen Asian paediatric liver transplant patients using a population PK analysis, and to 
elucidate any significant clinical or demographic effects that might necessitate dosage 
adjustments. To verify the predictive performance of the population PK model, 
subsequent Tac blood concentrations were predicted for an independent group of four 
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3.2. Methods           
 
Tac assay           
  
     Whole blood concentrations of Tac were measured by a competitive binding 
microparticle enzyme immunoassay (MEIA) with a procedure using an Abbott IMx 
analyser (Abbott, Chicago, IL, U.S.A.) (Grenier et al., 1991) by the hospital’s clinical 
laboratory. The lower limit of quantification of the assay was 5 ng/mL and it was linear 
between 4.5 ng/mL to 30.0 ng/mL. The between-day coefficient of variation (CV) of the 
assay was 16.0 % at a concentration of 5 ng/mL, 9.0 % at a concentration of 10 ng/mL, 
and 10.0 % at a concentration of 20 ng/mL. The within-day CV of the assay was 8.7 % at 
a concentration of 5 ng/mL, and 5.0 % at the concentrations of 10 ng/mL and 20 ng/mL.  
 
Population PK Modeling 
      
 The PK of Tac was determined using a population approach in which 
concentrations from all patients were analysed simultaneously to produce estimates of the 
PK parameters. In general terms, a population model consists of three sub-models. The 
structural model relates the independent variable, for example time, to the observations 
(e.g. drug concentrations in the blood). The covariate model relates the available 
demographic information such as age, gender and clinical laboratory measurements to the 
parameters of the structural model. The statistical model describes the differences 
between (1) the parameter values of the typical individual in the population under study 
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to the individual values of the parameters and (2) the observations and the model 
predictions, which are the residuals (Boeckmann et al., 1992). 
 Blood concentration-time profiles in the database were used for non-linear mixed 
effect modeling by extended least squares regression using the NONMEM computer 
program (Version IV, level 2.0), with double precision (Boeckmann et al., 1992), 
installed on a Pentium II 300 MHz personal computer (Aris, Exprez-series). Fortran 
subroutines were complied under Microsoft FORTRAN Powerstation (Version 4.00).  
  
 The first-order estimation method was used to estimate population mean 
parameters, intersubject variability in these parameters and residual intrasubject 
variability between observed and predicted Tac concentrations. The concentration-time 
course of Tac was described by using a one-compartment model with first-order 
absorption and elimination. The model was parameterized in terms of CL, V and F and 
implemented using the data preprocessor NMTRAN and PREDPP. The absorption rate 
constant, ka of the model was fixed at 4.5 hr 
-1, as a result of a sensitivity analysis carried 
out to determine the value of ka to be used in the NONMEM analysis. 
 
Pharmacostatistic modeling 
               
 A constant coefficient of variation model was used to describe the deviations of Tac 
CL (CLj), V (Vj) and F (Fj) of the jth individual from the true (but unknown) population 
mean values. 
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CL j  =  TVCL • ( 1 +  η j , CL ) 
       V j  =  TVV  • ( 1 +  η j , V ) 
        F j   =  TVF  • ( 1 +  η j , F ) 
 
TVCL, TVV and TVF are the population mean values for CL, V and F, respectively.              
η j , CL , η j , V and η j , F are random variables that distinguish the jth individual’s parameter 
from the population mean as predicted by the regression model and are assumed to be 
independent and normally distributed with mean zero and variance ω2. The magnitude of 
interpatient variability in the structural parameters was expressed as a CV. 
 
 An additive model was used to describe the residual error (∈) between the observed 
(C) and the predicted (Cpred) concentrations for the jth individual. These differences (∈ij) 
are attributable to intrapatient variability in PK parameters over time, assay error, 
sampling and dosing time errors, interoccasional variability, misspecification of the PK 
model and the influences of covariates which are either not included, or unknown. 
 
 
    C ij   =  C pred, ij   + ∈ ij  
 
 C ij  is the ith observed concentration for the jth individual. C pred, ij  is the blood Tac 
concentration predicted by the PK model. ∈ ij  is a randomly distributed variable with zero 
mean and variance of σ2. The magnitude of residual variability was expressed as a 
standard deviation (s.d.).      
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Regression model 
                
 The initial analysis for the population PK of Tac was conducted without including 
any patient covariates in the model (BASE 1). The value of the objective function (OBJF) 
from this model was then used as the reference in the subsequent univariate analyses 
whereby the influence of the patients’ covariates on CL, V and F was individually 
assessed. The regression relationship for CL was modeled as follows for continuous 
covariates:  
            
   TVCL  =  ΘCL
CL
 • ( covariate/median )     
   TVCL  =  Θ  • ( covariate/median ) 1COVCLΘ  
   TVCL  =  
CLΘ  +  1COVCLΘ  • ( covariate – median ) 
    
and as follows for dichotomous covariates (assigned a value of 0 or 1): 
 
   TVCL  =  ΘCL  • ( 1 - 1COVCLΘ  • covariate  ) 
with Θ 1COVCL  representing the regression coefficients to be estimated by the NONMEM 
analysis.  
      
 The following potential covariates were screened: patient age (AGE); weight (WT); 
height (HT); body surface area (BSA); gender (GEN); number of post-operative days 
(POD); alkaline phosphatase (APH); alanine amino transferase (ALT); aspartate amino 
transferase (AST); gamma glutamyl transferase (GGT); total bilirubin (TOTBIL); 
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albumin (ALB); total protein (PROT); lactate dehydrogenase (LDH); serum creatinine 
(CREA); serum urea (UREA) and haematocrit (HCT). These covariates were chosen as 
they represent clinical indicators of patient demographics, liver function and renal 




                
 For each model, the improvement in the fit obtained on addition of a fixed effect 
variable into the overall model was assessed by several means. Hierarchic models were 
compared statistically using a likelihood ratio test. The change in the objective function 
value (∆OBJF) produced by the inclusion of a covariate represents a statistic which is 
proportional to minus twice the log-likelihood of the data and approximates a χ2 
distribution with degrees of freedom equal to the difference in the number of structural 
parameters (i.e. θs) between two models (Neyman and Pearson, 1933). For non-
hierarchical models, the comparison was based on direct comparison of OBJF values and 
on visual inspection of the residual plots. A change in OBJF of  ≥  7.88 is required to 
reach statistical significance (p = 0.005) for the addition of one fixed effect (Neyman and 
Pearson, 1933). 
  
 The goodness-of-fit of each model was also assessed by the examination of the 
scatterplot of weighted residuals vs predicted Tac concentrations, the precision of the 
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parameter estimate (i.e. % standard errors of the mean and 95 % confidence interval) and 
by the magnitude of the interpatient and residual variability. 
 
     As a result of the univariate analysis, each model with significant effect (i.e. which 
satisfied all the above-mentioned criteria) was ranked according to its ∆OBJF compared 
with BASE 1. The model with the largest ∆OBJF was designated as BASE 2 and multiple 
regression analysis with forward selection was performed where covariates were 
incorporated into BASE 2 one by one, starting with the second largest ∆OBJF and 
continuing along the rank order established in the univariate analysis. Each covariate that 
caused a ∆OBJF of  ≥ 7.88 was kept in the model. The model, BASE 3, containing all 
significant covariates was then subjected to stepwise, backwards elimination where each 
coefficient for a covariate was set to zero, in turn; the final model contained only those 
covariates whose omission caused an increase in OBJF of ≥ 7.88.     
  
Model evaluation 
                
 To verify the predictive value of the population model, the measured Tac 
concentrations in the validation group (n = 4) were compared with the corresponding 
predicted values by the population model using posthoc Bayesian forecasting. This was 
achieved by fixing the structural and variance model parameters to the values estimated 
in the final population model.         
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 The predictive performance of the model was assessed in terms of bias (mean 
prediction error, ME) and precision (root mean square prediction error, RMSE) and the 
associated 95 % confidence intervals(Sheiner and Beal, 1981). Weighted residuals were 
plotted against the predicted concentrations to visually assess the deviations among pairs 
of model-predicted and observed blood Tac concentrations in the validation group. 
            
3.3.  Results            
 
Study population and data collection        
  
     Data were obtained retrospectively from medical records and routine Tac 
monitoring of paediatric patients who underwent orthotopic liver transplantation between 
Jun 1996 and Aug 1999 at the National University Hospital, Singapore. Information 
extracted from the medical records included date, time, postoperative day, dose of Tac, 
Tac blood concentration, age, height, current body weight, gender, liver function indices, 
renal function indices and haematocrit. The information was checked as thoroughly as 
possible for accuracy. To ensure the accuracy of the data, dosing information and 
laboratory results as recorded on the patient’s medical records were confirmed by 
referring to the original medicine administration record and clinical laboratory results, 
respectively. 
  
 The total number of patients included in this analysis was based on the availability 
of patients who underwent orthotopic liver transplantation between Jun 1996 and Aug 
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1999 at the National University Hospital, Singapore. Patients were assigned randomly to 
either an index group (n = 16) for development of the PK model(s), or to the validation 
group (n = 4) for the purpose of assessing the predictive performance of the derived 
model(s) with characteristics as shown in Table 7. The choice for the number of patients 
to be included in the validation group is based on the accepted practice of including half 
to one-third the number of patients in the index group in population modeling. 
  
Tac administration           
 
 In four patients, oral Tac was given preoperatively at a dose of 0.3 mg/kg/day for 
one day. Postoperative immunosuppressive therapy consisted of a combination of 
steroids and Tac. In ten patients, Tac was administered IV intraoperatively at a dose of 
0.05 mg/kg, which was followed postoperatively by a 24 hr continuous IV infusion at an 
initial dose of 0.05 mg/kg/day for 3-7 days. In ten patients, Tac was commenced enterally 
via a nasogastric tube starting on the second postoperative day. When oral intake was 
started, it was given at a dose of 0.2 mg/kg/day in two divided doses. Dosing adjustments 







    







   
Number (M/F) 16 (8/8) 4 (2/2) 
Age (yr) 3.7 (1.1 – 13.9) 2.0 (1.2 – 4.0) 
Height (cm) 84.3 (68 – 116) 80.5 (73 – 98) 
Weight (kg) 12.0 (6.9 – 20.5) 10.3 (8.0 – 14.6) 
Race   
     Chinese 10 4 
     Malay 4  
     Indian 2  
Tac   
     Blood concentration (ng/mL) 12.7 (5.0 – 49.8) 12.7 (5.0 – 30.0) 
     Number of samples 771 86 
     Median samples per patient 44 (19-80) 20 (6-40) 
 
Table 7.  Characteristics of patients included in the study. Results are presented as the 
number, or mean (range). 
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Pharmacostatistic modeling  
         
     In the initial model, the data were better described with a one-compartment model 
with first-order absorption and elimination (subroutines ADVAN 2 TRANS 2) than 
onewithout considering first-order absorption (subroutines ADVAN 1 TRANS 2), as 
noted by a greater reduction of the OBJF of 27.0 ( p < 0.001 ) and an improvement in the 
precision in the estimation ω2F (coefficient of variation decreases from 422.8 % to 48.3 
%).  
 
  The one-compartment with first-order absorption and elimination model after oral 










××= 0)()(  
 
where ka is the absorption rate constant, ke the elimination rate constant, D the dosage 
given to the patient, t the time, C0 the initial concentration, and Cp the predicted 
concentration. A diagrammatic representation of this PK model is shown in Figure 3. 
 
     ka   ke 
 
      Compartment 1 
Figure 3. A schematic representation of the one-compartment with first-order absorption 
and elimination PK model.   
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 As most of the kinetic data were collected in the postabsorption phase, ka could not 
be reliably estimated; for this reason, its value was empirically estimated and then fixed 
throughout the analysis. A sensitivity analysis showed that the lowest estimate errors for 
the parameters were obtained by fixing ka to a value of 4.5 hr 
–1 after testing in the basic 
model with ka values increasing in interval of 1 from 0.5 to 7.5 hr 
–1 (Table 8). 
 
 For the residual variability, the OBJF with use of an additive, slope/intercept and 
power error models was 1016 lower than that with use of proportional and exponential 
error models. However, the standard errors of parameter estimates were higher for the 
slope/intercept and power models (Table 9). Thus an additive error model for residual 
variability was used in the basic PK model (BASE 1) to be used for further analysis. 
 
Regression models           
  
 Results of the univariate analyses showing covariates with significant effects on 
CL, V and F of Tac in paediatric patients are presented in Table 10. The regression 
relationship for TOTBIL on F was estimated initially using models for a continuous 
covariate, the best of which satisfied four out of the five criteria for model discrimination. 
Thus a categorical “cutoff” model was used, which caused the model to satisfy all the 
criteria used in model discrimination. Hence, this relationship was used to model the 
effect of TOTBIL on F. The covariate model causing the largest reduction in OBJF (i.e. 
linear model of weight on F) was declared as BASE 2, which acted as a reference model 
for the subsequent analysis of building a more complex model. 
    
       




     
     ka (hr
-1)           Min. obj. fn.                                                      S td. error of parameter estimation (CV%) 
                                                                  θCL                θV                  θF               ω2CL                ω2V                        ω2F                              σ  2 
 
      
     0.5                 -6939.836                      24.3               58.7               27.7             44.0                91.0               49.4                  18.4 
 
     1.5                 -6962.150                      23.4               49.4               26.3             44.2                67.1               48.7                  18.9 
 
     2.5                 -6966.575                      23.2               48.1               26.2             44.3                65.1               48.4                  19.0 
 
     3.5                 -6967.900                      23.2               47.7               26.0             44.1                64.8               48.2                  19.0 
 
     4.5                 -6968.367                      23.2               47.4               25.9             44.1                64.8               48.2                  19.1            
 
     5.5                 -6968.551                      23.2               47.4               26.0             44.1                65.0               48.4                  19.1 
 
     6.5                 -6968.632                      23.2               47.7               25.9             44.3                64.8               48.1                  19.1            
 





Table 8. Sensitivity analysis of ka values used in ADVAN 2 TRANS 2 subroutine. 
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Table 9. Comparison of interpatient and intrapatient random effects models. 
 
                        Model                                                                         S td. error of parameter estimation (CV%) 
________________________                                  _______________________________________________________________ 
  Interpatient       Intrapatient        Min. obj. fn.        θCL      θV         θF          θ6           ω2CL         ω2V                ω2F                  σ1  2                 σ1  2 
 
     
  Additivea           Additivec            -6982.284        20.3      39.9      24.4                      44.5         57.7         51.2           19.0                        
 
  Additive            Proportionald      -5952.650        20.1      23.0      25.0                      38.8         71.5        562.3           28.7 
 
  Additive            Slope/intercepte  -6982.284        20.3      39.9      24.4                      44.6         57.5         51.0             2.3×107   19.0 
 
  Additive            Exponentialf        -5952.650       20.1      23.0      25.0                      38.8         71.5        562.3           28.7 
 
  Additive            Powerg                 -6982.284       19.9      39.9      24.3    2.96×108   44.5         58.3         50.7          102.7 
 
 
  Proportionalb     Additive              -6968.367        23.2     47.4      25.9                      44.1         64.8         48.2            19.1 
 
  Proportional      Proportional        -5952.571        20.2     21.9      29.0                      22.8         38.8           1.47×108   26.0 
 
  Proportional      Slope/intercept    -6968.367        23.2    47.7       26.0                      44.1         64.8         48.0              4.7×105   19.1   
 
  Proportional      Exponential         -5952.571        20.2     21.9      29.0                      22.8         38.8           1.47×108   26.0 
 
  Proportional      Power                  -6968.367        23.2    47.7       25.9    6.76×104   44.1         64.8         47.9             19.1 
 
a Pj = PTV  + ηj  ; 
b Pj = PTV  × (1 + ηj);  
c Cij = Cpred, ij + εij  ;  
d Cij = Cpred, ij ×(1+ εij);  e Cij = Cpred, ij ×(1+ ε1, ij)+ ε2, ij ;  f Cij = Cpred, ij ×EXP(εij) ; 
g Cij = Cpred, ij + Cpred, ij 
θ6 .εij  
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Table 10.  Summary of univariate analysis showing covariate models with significant effects on CL, V or F of Tac. 
Effect 
on 
Model ∆OBJF a Parameter 
estimate 
95% CI b 
  lower            upper 
p value 
CL d 
CLΘ + 1AGECLΘ * (AGE-2.25) -19.842 CLΘ = 1.48 0.93 2.03  < 0.001
            ( 1 DF )  1AGE
CLΘ = 0.294 0.05   
   
   
   
   
   
   
   
   
   
   
   




VΘ + 1WTVΘ *(WT-11.4) -14.68 VΘ = 45.4 26.6 64.2 < 0.001
            ( 1 DF )  1WT
VΘ = 6.48 3.79 9.17
 
VΘ + 1BSAVΘ *(BSA-0.49) -16.83 VΘ = 45.4 26.9 63.9 < 0.001
            ( 1 DF )  1BSA
VΘ = 220 115.3 324.7
 
VΘ *(HCT/31.9)  1HCTVΘ -14.421 VΘ = 46.7 6.13 87.3 < 0.001
            ( 1 DF )  1HCT
VΘ = -0.688 -1.13 -0.25
F f 
FΘ *(AGE/2.25)  1AGEFΘ -16.271 FΘ = 0.178 0.11 0.25 < 0.001
         ( 1 DF )  1AGE
FΘ = 0.484 0.20 0.76
 
FΘ + 1WTFΘ *(WT-11.4) -36.574 FΘ = 0.185 0.13 0.24 < 0.001
           ( 1 DF )  1WT
FΘ = 0.0204 0.01 0.03
 
FΘ + 1HTFΘ *(HT-82) -23.518 FΘ = 0.187 0.12 0.26 < 0.001
          ( 1 DF )  1HT
FΘ = 0.00609 0.001 0.011
 
FΘ  
IF TOTBIL ≥ 200 µmol/L, FΘ * 1TOTBFΘ  
 
-17.02 
FΘ = 0.193 
1TOTB






                  ( 1 DF ) 
Θ
     
 
F *(BSA/0.49) -27.286 FΘ = 0.183 0.12 0.24 N.A.c 
a Reduction in the OBJF in comparison to the basic model (BASE 1). A ∆OBJF ≥ 7.9 and 10.6 is statistically significant (p < 0.005) 
for 1 and 2 degrees of freedom (DF), respectively. b CI = confidence interval. c N.A., statistical test inappropriate as it is a non-
hierarchical model. d CL = 1.46 L/hr in BASE 1. e V = 39.1 L in BASE 1. f F = 0.197 in BASE 1.
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 The results of multivariate analyses with forward selection, incorporating the 
covariates with significant effects into BASE 2 one by one in decreasing order of reduction 
in OBJF are presented in Table 11. In the presence of the effect of WT on F, BSA and HT 
no longer had a significant effect on F. However, the effects of AGE on CL, TOTBIL on F 
and BSA on V remained significant. In the subsequent models, the effects of AGE on F, WT 
and HCT on V were no longer significant. Thus, a model incorporating the effects of AGE 
on CL, BSA on V, WT and TOTBIL on F was selected as BASE 3. 
 
 Backward elimination from BASE 3 showed that the effects of AGE on CL, BSA on 
V, body WT and TOTBIL on F remained statistically significant; the model incorporating 
these factors was declared the final model for Tac population PK. An adequate correlation 
between predicted and observed whole blood Tac concentrations was observed in the final 




                
 Mean prediction error (ME) between measured and predicted blood Tac concentrations 
in the validation group (n = 4) of paediatric liver transplant patients was 1.4 ng/mL (95 % 
CI: -0.025, 2.81). Thus there was a statistically insignificant bias between the measured and 
predicted blood Tac concentrations. The root mean square error (RMSE) associated with the 
validation group was 6.7 ng/mL (95 % CI: 5.58, 7.68), which is similar to the intrapatient 
s.d. for the population group of 5.8 ng/mL. The scatterplot of weighted residual versus 
predicted whole blood Tac concentration (Figure 5) showed that the weighted residuals were  
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Table 11.  Summary of multivariate analyses with forward selection. 
 
Effect ∆OBJF a Improvement b 
   
WT on F - - 
(BASE 2)   
   
BSA on F 2.728 No 
   
HT on F -1.283 No 
   
AGE on CL -30.037 Yes 
   
TOTBIL on F -8.294 Yes 
   
BSA on V -19.892 Yes c 
   
AGE on F 4.109 No 
   
WT on V 6.787 No 
   
HCT on V -3.297 No 
   
a Change in OBJF in comparison to preceding model with an advantage. 
 b Advantage on preceding model with significant effect (based on ∆OBJF and 95% 
confidence interval). 
c This model which incorporates the effects of AGE on CL, BSA on V, WT and TOTBIL on 
F was selected as BASE 3.  
     
































Figure 4.  Scatterplot of predicted versus observed Tac whole blood concentration in the 







     





















Figure 5.  Predictive performance of the final model (n = 4 patients). Scatterplot of 
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randomly distributed and mostly lay within ± 2 units of the null ordinate of perfect 
agreement. Specific examples of the predictive capability of the final optimal model are 
shown for two representative individual patients in the validation dataset in Figure 6, which 
shows the time-course of measured and posthoc predicted whole blood Tac concentrations. 
 
Final population PK model  
                
 The final computed population parameter estimates, the interpatient and residual 
variability and the precision of the estimates obtained by fitting the full dataset are presented 
in Table 12. For a hypothetical patient with population median values of AGE, BSA and 
body WT (i.e. 2.25 years old, 0.49 m2 and 11.4 kg), the model-predicted CL, V and F would 
be 1.46 L/hr, 39.1 L and 0.197, respectively. The F would increase by 61 % to 0.317 if the 
TOTBIL was ≥ 200 µmol/L. The model for CL found that CL changed by 34 % for every 1 
year above and below 2.25 year (the median AGE), resulting in an estimated range of 0.88 – 
7.23 L/hr across the AGE range of 1.07 – 13.9 year. The model for V indicated that V 
changed by 46 % for every 0.1 m2 above and below 0.49 m2 (the median BSA), which 
resulted in an estimated range of 15.9 – 96.3 L across the BSA range of 0.36 – 0.81 m2. The 
model for F showed that it changed by 0.09 % for every 1 kg above and below 11.4 kg (the 
median body WT) giving an estimated range of 0.118 – 0.356 across the body WT range of 
6.9 – 20.5 kg. Profile of age-normalised CL (predicted by the population model) vs AGE of 
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Figure 6. Longitudinal assessment of the predictive performance of the final population 
model in 2 representative patients from the validation dataset: (a) 1 year-old male (b) 1 year-
old female. (●) observed and (■) model-predicted whole blood Tac concentration. 
 
     



































Figure 7. Profile of age-normalised CL (predicted by the population model) vs AGE of 
patient. 
     
        
                      
Table 12.  Postliver transplantation population PK of Tac after IV and oral administration in Asian paediatric patients. 




Precision of estimation 
Std. error          CV (%)   
CL 
CLΘ  L/hr   1.46 0.174 11.9
V 
VΘ  L    
    
   
   
   
    
    
    
    
  
    





FΘ  0.197 0.0263 13.4
Factor for AGE on CL 1AGE
CLΘ  yr-1 0.339 0.0675 19.9
Factor for BSA on V 1BSA
VΘ  m-2 4.57 0.983 21.5
Factor for body WT on F 1WT
FΘ  kg-1 0.0887 0.0228 25.7
Factor for TOTBIL ≥ 200 µmol/L on F TOTBIL
FΘ  1.61 0.0991 6.16
Interpatient variance of CLj about CLTV ω2CL 0.112 0.0446 39.8
Interpatient variance of Vj about VTV ω2V 0.109 0.0756 69.4
Interpatient variance of Fj about FTV ω2F 0.0579 0.0451
 
77.9
 CV of CLj about CLTV CVCL % 33.5
CV of Vj about VTV CVV % 33.0
CV of Fj about FTV CVF %
 
24.1





Standard deviation of Cij about Cpred, ij  σ ng/mL 5.79
Structural models: TVCL = *CLΘ  [ 1 + *1AGECLΘ  (AGE – 2.25) ] 
   TV = V *V 
F 
Θ  [ 1 + *1BSAVΘ  (BSA – 0.49) ] 
   TV = F *Θ  [ 1 + *1WTFΘ  (WT – 11.4) ] * [ (1 – Y) + Y* TOTBILFΘ  ] 
 Random effects models:  CLj = TVCL * ( 1 + ηj, CL ) 
    Vj = TVV * ( 1 + ηj, V ) 
    Fj = TVF  * ( 1 + ηj, F ) 
    Cij  = Cpred, ij  + εij  
where, AGE = age in year; BSA = body  surface area in m2; WT = body  weight in kg; TVCL = typical population value for CL; TVV = typical population value for V; TVF = typical population value 
for F; and the value of Y is 0 for total bilirubin < 200 µmol/L. The Y value for total bilirubin ≥ 200 µmol/L is 1.  
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 The interpatient variability (CV %) for the population PK parameters of CL, V and 
F was large and ranged from 24-34 % (Table 12). The intrapatient s.d. was 5.79 ng/mL, 
which translates to a CV % of 45.6 % at the mean blood concentration of Tac (12.7 
ng/mL) measured in the population dataset. The imprecision (calculated by dividing the 
standard error of each parameter by its value and expressed as a percentage) in estimating 
the random effect parameter estimates was greater than that of the fixed effect parameter 
estimates. 
 
3.4.  Discussion          
            
 In this study, the PK of Tac were investigated in Asian paediatric liver transplant 
patients by a population modeling approach. This is particularly suitable as ethical and 
logistical restrictions involved in studying children prohibit extensive blood sampling, 
compared with traditional PK studies (Kauffman and Kearns, 1992). Large physiological 
and maturational changes occur in paediatric patients as they are in a rapid stage of 
development, thus producing potentially greater impact on the PK and therefore may be 
at greater risk from inadequate dosing. However, it must be noted that while this 
approach allows the development of a population model and the identification of 
potential covariates, the results needs to be verified in prospective PK studies. 
 
     Tac is extensively metabolised in the liver and undergoes biliary excretion 
(Venkataramanan et al., 1995). In this study, part of the interindividual variability in CL 
was explained by differences in the AGE of the patient. The interindividual variability of 
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CL in BASE 1 was 53.9 %; however, on considering the patient’s AGE, this variability 
was reduced to 33.5 %. From the general principles of developmental pharmacology 
(Yaffe and Aranda, 1992; Radde and MacLeod, 1993), it would be expected that a highly 
lipophilic drug, such as Tac, eliminated primarily by biotransformation, will show age-
related differences in its PK. In addition, as a result of dosage problems and rapid 
changes in clinical condition, growth and maturation would cause further intraindividual 
differences. 
 
     The mean population CL value of Tac found in this study was 0.125 L/hr/kg 
(obtained by normalising the mean population CL value of 1.46 L/hr by the population 
mean body weight of 11.65 kg for the 20 patients), which closely agreed with the 0.138 
L/hr/kg obtained by the traditional approach used in one study on paediatric patients 
(Wallemacq et al., 1998). This is about twice the mean CL of 0.0541 L/hr/kg (Jusko et 
al., 1995a) and 0.0528 L/hr/kg (Lee et al., 1993) previously estimated in adult liver 
transplant recipients and could account for the findings that paediatric patients require 
higher doses of Tac on a mg/kg basis than adults (Jain et al., 1991; McDiarmid et al., 
1993).  
 
     The dependence of Tac CL normalised for age with age (Figure 7) indicates a 
decrease in age-normalised CL with increasing age.  The physiological basis for age-
related decrease in age-normalised CL is unknown but may be related to changes in 
hepatic metabolic function with age. Studies of alterations in rates of hepatic metabolism 
for a wide variety of pharmacologic agents as a function of increasing age have indicated 
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that, whereas nonmicrosomal metabolism and Phase II conjugation processes are 
minimally affected, the activity of the microsomal mixed function oxidase (MFO) system 
decreases progressively with increasing age (Munson et al., 1996). Thus the hepatic 
metabolism of Tac decreases with increasing age as Tac can undergo biotransformation 
both by the MFO and conjugation (Venkataramanan et al., 1995). Many drugs that are 
biotransformed by oxidation are more rapidly metabolised during childhood than in 
adulthood, particularly if the drug CL is normalised to body WT. Examples of drugs with 
higher rates of biotransformation during childhood include theophylline, phenobarbital 
and phenytoin (Heimann and Gladtke, 1977; Blain et al., 1981; Chiba, 1991). The 
activities of many components of the mono-oxygenase system are higher in children 
under 12 years of age and to a lesser extent during puberty, than in adults (Radde and 
MacLeod, 1993). 
  
 As reported in a previous paediatrics study (Yasuhara et al., 1995), the CL of Tac 
correlated with the number of postoperative days (POD) and body size (expressed as 
body weight raised by to the power of 0.29). The correlation with POD was attributed to 
change in hepatic function with POD, but in the present study no such correlation was 
found. A previous population PK analysis of Tac in adults (Mekki and Lee, 1994) 
showed that mild to moderate hepatic dysfunction did not affect the CL of Tac, which 
was also found in our paediatric patients. However, it should be noted that only one 
patient in our population dataset suffered from severe hepatic dysfunction over a 
sustained period. 
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     Indices of renal function (serum CREA and serum UREA), GEN, BSA, HCT and 
ALB had no significant effect on the CL of Tac. The lack of effect of indices of renal 
function on CL is plausible since the renal CL of Tac accounts for less than 1 % of total 
systemic CL (Venkataramanan et al., 1991). 
 
 Tac is a low-CL drug; the extraction ratio is equivalent to about 3 % of liver blood 
flow (Undre et al., 1999). For a highly bound, low-extraction ratio drug like Tac, CL 
would be affected by changes in HCT and plasma protein binding. Indeed, trough whole-
blood concentrations of Tac after renal transplantation correlate with HCT and ALB 
during the first weeks of treatment and its relative CL was negatively correlated with 
HCT and ALB (Undre and Schäfer, 1998). The lack of significant effect of HCT and 
ALB on CL in the current study could be attributed to the limited range of HCT and ALB 
concentrations in our patients.  
 
     Part of the interindividual variability in the V of Tac was explained by differences 
in the BSA of the patient. The interindividual variability of V in BASE 1 was 61.2 %; 
however, on considering the patient’s BSA, this variability in V was reduced to 33.0 %. 
Therefore, BSA is a good indicator of the V in this group of paediatric patients. Body WT 
raised to a power of 0.29 is used as an indicator of body size to model the influence of 
body WT on V in a previous report in paediatric liver transplant patients (Yasuhara et al., 
1995). Although both the body WT and BSA had significant effects on V during the 
univariate analysis in this study, BSA was found to be a better predictor of V than body 
WT. This may be because the body WT measured in these patients is not an accurate 
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reflection of lean body mass as most of the time there is an accumulation of extracellular 
fluid (in the form of ascites fluid) in these patients. Thus, the body WT in this group of 
patients is variable and is susceptible to fluctuating values depending on the clinical 
condition of the patient. Thus, the incorporation of body HT with body WT in the form of 
BSA gives a better indicator of body size and hence predictor of V, as HT is not 
susceptible to wide fluctuations in values. 
 
     The mean population V value of Tac found in this study was 3.36 L/kg (obtained by 
normalising the mean population V value of 39.1 L by the population mean body WT of 
11.65 kg for the 20 patients). This is in reasonable agreement with the V values of 2.6 
L/kg and 41.41 L determined in a traditional PK study in paediatric patients (Wallemacq 
et al., 1998) and a population PK study (Yasuhara et al., 1995), respectively. However, 
this is about three times the mean value of V of 0.906 L/kg reported in the adult liver 
transplant recipients (Jusko et al., 1995a). The V decreases with increasing age, which 
may be due to age-related changes in binding substances such as HCT with age (Natha 
and Oski, 1987), which would affect the distribution of the drug within the body. This is 
because Tac is extensively distributed into red blood cells, and the whole blood to plasma 
ratio ranges are greater than 30-10 over low to high plasma concentrations (Jusko and 
D'Ambrosio, 1991; Backman et al., 1994). Therefore, changes in HCT would alter the 
distribution of Tac between blood and fat since it is a lipophilic compound. The highest 
normal HCT value (0.61 L/L) is seen in newborns, followed by a gradual decrease to 
reach a nadir at 2 months of age. The HCT then increases until normal adult values 
(about 0.45 L/L) are reached at 14 years of age. Thus, the increase in the HCT from 2 
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months to 14 years of age could decrease the partitioning of Tac into fat, thereby 
decreasing its distribution. This hypothesis is supported by the finding that HCT was a 
significant covariate affecting V during the univariate analysis; an increase in HCT 
resulted in a decrease in V, via a power function. However, this model failed to be 
included in BASE 3 during subsequent multivariate analysis with forward addition. This 
does not mean that the HCT is not important; it simply reflects a lack of variability within 
the patient group that is not already accounted for by the effect of BSA on V. If a wider 
range of HCT had been present, it is likely that HCT would have had a significant 
influence on V. 
 
     GEN of the patient has no effect on V of Tac as shown in this study. Adult females 
have a higher proportion of body WT as fat than males, therefore GEN-related difference 
in V might be anticipated for Tac. However, all patients were pre-pubertal, which may 
explain the lack of GEN-related differences in body fat content in our patients.    
 
     Part of the interindividual variability in the F of Tac was explained by differences in 
the body WT and TOTBIL. The interindividual variability of F in BASE 1 was 35.2 %; 
however, on including the patient’s body WT and TOTBIL, this variability is reduced to 
24.1 % in the final population model. Thus the F of Tac is affected by two factors: the 
development and growth of the patient, and the liver function of the patient. 
 
     Since the extent of drug absorption is proportional to the area available for 
absorption, bowel length is a determinant of drug absorption, as reported for cyclosporine 
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(Whitington et al., 1990). Hence the dependence of F on the development and growth of 
the paediatric patient is not surprising as the gastrointestinal tract undergoes considerable 
developmental changes during the first years of life (Motil, 1993). It has been found that 
the main factor contributing to increasing bowel length up to about 4 years of age is 
increasing body size (Seibert, 1980). Predictors of body size such as body WT, HT and 
surface area were all significant covariates affecting the F during the univariate analysis, 
but only body WT remained as a significant covariate during subsequent multivariate 
analysis. The discrepancy between the V and F models using different covariates as 
indicators of body size can be attributed to nondevelopmental factors affecting the bowel 
length such as surgical excision of part of the bowel during liver transplantation, or 
during Kansai portoenterostomy. 
 
     The liver function of the patient as indicated by the TOTBIL is found to affect the F 
of Tac. Paediatric patients with a TOTBIL ≥ 200 µmol/L had a 61 % greater F compared 
with those with lesser concentrations of bilirubin. This may be due to reduced first-pass 
effect in patients with hepatic dysfunction compared with patients with normal hepatic 
function resulting in higher F. This is supported by the finding in a study that a higher 
oral F of 36 % was noted in patients with moderate to severe liver impairment after 
infusion of Tac 0.15 mg/kg or an oral dose of 0.15 mg/kg (Jain et al., 1990). 
 
     The mean population F calculated in the present study compared favourably with 
the value of 0.197 obtained in one study (Yasuhara et al., 1995) using a population PK 
approach, and the value of 0.25 obtained in another study (Wallemacq et al., 1998) in 
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paediatric patients using a traditional approach. Mean values of 0.25 and 0.238 were 
reported in adult liver transplant patients in a traditional PK study (Jusko et al., 1995a), 
and in a population PK study (Mekki and Lee, 1994), respectively. Thus, Tac has a 
relatively low oral F both in paediatric and adult liver transplant patients. 
 
     The residual (unexplained) variability was quite large, reflecting perhaps large 
intraindividual variability in the PK, interoccasion variability, assay errors, sampling time 
errors and model misspecification. This variability may be reduced if a prospective study 
design is used which provides tighter control on some of the above factors. 
 
         In this study, the effects of covariates which have an influence on the PK 
parameters of Tac in paediatric liver transplant patients are due to a difference of 
covariates between patients and the change within a patient for that covariate. This is 
because in many patients, the data were collected for a duration of several months, which 
will result in changes of covariate values within a patient. One limitation of the current 
study is that only a small number of patients (n = 20) was used for analysis. The ability to 
encounter and quantify many covariates is quite limited in such a small group. However, 
this was the number of paediatric patients that were currently available at the time of this 
analysis, as there were 22 paediatric liver transplantations performed during the period 
1995 to May 1999 (two retransplants) (Wai et al., 2000) at National University Hospital, 
Singapore. 
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 Therefore the purpose of this population analysis is mainly hypothesis-generating, 
ie. producing hypothesis of the effects of covariates on the PK parameters. This 
population model can be tested and refined using data from future prospective studies 
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4.1. Study Aims 
 
The objective of the study is to prospectively describe the population PK of Tac 
following oral administration in Asian adult and paediatric liver transplant patients, and 
to identify and quantify the influence of patient characteristics on the PK of Tac.        
 
The previous study in this thesis has focused on the same aspects but in a sub-
population i.e. paediatric patients. A hypothesis regarding the effect of HCT on the V of 
Tac was made based on the findings in the study. It is of interest to verify this hypothesis 
on a wider range of HCT. This is only possible if adult patients are included in the same 
study to allow the effect to be investigated and quantified. In general, a population model 
built from a more heterogenous population allows an easier determination of the effect of 
covariates on the PK parameters because a wider range of values for the covariates can be 
encountered. 
       
4.2.  Methods                                        
 
4.2.1. Chemicals and materials          
                                  
 The following drugs and chemicals were kindly provided by or obtained from the 
sources indicated: Tac (FK-506) (Fujisawa Pharmaceuticals Co., Osaka, Japan), 
ascomycin (BioChemika, Fluka Chemie AG and RdH Laborchemikalien GmbH & Co. 
KG), HPLC-grade solvents such as acetonitrile and methanol used in extraction or 
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analytical procedures (Fisher Chemical, Fisher Scientific, Fair Lawn, New Jersey), 
ammonium formate (Analar grade) (BDH Chemicals, Poole, U.K.), acetic acid (ACS 
grade) (Sigma Chemical, St. Louis, MO), zinc sulphate (Merck, Darmstadt, Germany). 
Deionized (18 mΩ ) water (Milli-Q water system; Millipore Inc., Bedford, MA) was used. 
          
 Ascomycin is a structural analogue of Tac. The chemical structure of ascomycin is 
























   
Figure 8.  Chemical structure of ascomycin. 
 
4.2.2. Preparation of standard, internal standard and quality controls 
            
 Two different Tac stock solutions of the same concentration were prepared 
separately, one of which was used for the preparation of calibration standards and the 
second for quality control samples. Tac stock solution I (1 mg/mL) was prepared fresh 
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with the weighing of Tac and dissolution in acetonitrile. Stock solution I was diluted 100-
fold with acetonitrile to yield stock solution II. Stock solution II (10 µg/mL) was diluted 
2000-, 500-, 100-, 50-, 20-, 10- and 5-fold with acetonitrile to produce 5, 20, 100, 200, 
500, 1000 and 2000 ng/mL working stocks of Tac, respectively. A 100 µL aliquot of each 
working stock was added to 1.90 mL of blank human whole blood to prepare whole 
blood calibration standards. A 100 µL aliquot of the 5, 20, 100, 200, and 500 ng/mL 
working stock was added to 1.90 mL of blank human plasma to prepare plasma 
calibration standards. 
 
 Ascomycin stock solution (1 mg/mL) was prepared in acetonitrile. This solution 
was diluted with acetonitrile to prepare a 2500 ng/mL working internal standard solution. 
Addition of 10 µL aliquots of the working solution to 1 mL human whole blood or 
plasma gave a concentration of 25 ng/mL. 
 
 Tac stock solution II (10 µg/mL) was diluted 2000-, 333.3-, 33.3- and 6.7-fold with 
acetonitrile to produce 5, 30, 300, and 1500 ng/mL working stocks of Tac, respectively. 
Whole blood quality controls were prepared by diluting 5.0 mL aliquots of these working 
stock solutions to 100 mL with blank human whole blood. Stock solution II (10 µg/mL) 
was diluted 2000-, 333.3-, 66.7- and 25-fold with acetonitrile to produce 5, 10, 150, and 
400 ng/mL working stocks of Tac, respectively. Plasma quality controls were prepared by 
diluting 5.0 mL aliquots of these working stock solutions to 100 mL with blank human 
plasma. 
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4.2.3. Calibration and validation 
 
 The determination of Tac was based on the internal standard method. The 
calibration curve was generated by plotting the peak area ratio of Tac to the internal 
standard, ascomycin, against the spiked concentration of Tac. A seven-point calibration 
curve (triplicate injections) was created for the range 0.25 – 100 ng/mL for the 
quantitation of Tac in human whole blood. A five-point calibration curve (triplicate 
injections) was created for the range 0.25 – 25 ng/mL for the quantitation of Tac in 
human plasma. Calibration curves for both whole blood and plasma matrices were 
evaluated by ordinary least-squares regression.  
 
 Assay performance was assessed by precision and accuracy of the standard 
concentrations used for the quality control samples. Precision was expressed as the 
percent CV at each concentration. Precision was calculated after the analysis of 6 
replicates on the same analytical run (intra-day) and after 3 repeated analyses on different 
days along different analytical runs (inter-day). Accuracy was calculated as the 
percentage of the added concentration multiplied by 100. 
 
 The extraction recoveries were determined from the whole blood and plasma 
samples used for the precision study. The mass spectrometer responses of the extracted 
samples were compared with the response after injection of respective amounts of Tac or 
ascomycin solutions directly on the analytical column.     
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4.2.4. Sample preparation                                                                
  
 The sample preparation method for Tac in human whole blood and plasma is 
adapted from a method for therapeutic monitoring of Tac in blood, with modifications 
(Lensmeyer and Poquette, 2001). The modifications involve the change from semi-
automated solid phase extraction to a fully manual procedure and the change from the use 
of styrene-divinylbenzene (SDB-XC) disk cartridge to a C18 reversed-phase disk 
cartridge.   
                                                                                             
Whole blood samples          
                                             
 1 mL of whole blood was spiked with 10 µL of ascomycin working standard 
solution. 2 mL of a 0.3M zinc sulphate:methanol (40:60 v/v) solution (protein 
precipitating solution) was added to the sample to precipitate the proteins. The sample 
was then vortexed, centrifuged at 20,000g for 10 minutes and the supernatant subjected to 
solid-phase extraction by use of a C18 7 mm/3 mL reversed-phase extraction disk 
cartridges (3M Empore™, Fisher Scientific, Fair Lawn, NJ) previously  preconditioned 
with methanol and water on a vacuum manifold (Varian Sample Preparation Products, 
Harbor City, CA). Tac was eluted with 3 mL of acetonitrile:water (90:10 v/v) and the 
eluant dried using a Savant SpeedVac® concentrator (Savant, Holbrook, NY). The dried 
sample was reconstituted in 60 µL of acetonitrile:water (90:10 v/v) and 20 µL was 
injected using a 25 µL micro-syringe (Hamilton Co., Reno, Nevada).                                     
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Plasma samples                   
                                                         
 The same procedures were used for preparing the plasma samples except that 2 mL 
of samples, 20 µL of internal standard solution and 3 mL of protein precipitating solution 
were used. 
 
4.2.5. Blood sampling         
  
 Venous blood samples (6.5 mL) were taken from an arm vein just before a dose and 
at specific time points after an oral dose of tacrolimus. Blood samples were divided over 
two EDTA Vacutainer® Plus blood collection tubes (Becton Dickinson, Franklin Lakes, 
NJ). One 1-mL whole blood sample was stored at –80ºC until the time of drug assay. The 
other blood sample was incubated at 37ºC in a water bath for 2 hours before centrifuging 
for 10 minutes at 3000 rpm at the same temperature. Separated plasma was aspirated with 
a disposable pipette and transferred to a 2.5 mL plastic tube. The plasma sample was also 
stored at –80ºC until assayed for Tac.            
                                                                                                                                 
4.2.6. Bioanalytical assay          
            
 Whole blood and plasma concentrations of Tac were determined using an 
electrospray high-performance liquid chromatographic/mass spectrophotometric/mass 
spectrophotometric (HPLC/MS/MS) assay. This assay was modified from an assay 
published by Taylor et al (Taylor et al., 1996). The modifications include the change of 
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the organic solvent used in liquid chromatography from methanol to acetonitrile, the flow 
rate of the mobile phase decreased from 0.1 ml/min to 0.05 ml/min and the column was 
changed from a C4 reversed phase 30 mm × 2.1 mm column to a C18 reversed phase 50 
mm × 1.0 mm column.  
 
 The HPLC/MS/MS system consisted of a Shimadzu (Kyoto, Japan) LC-10 AD 
microbore HPLC with a binary pump and 15 µL gradient mixing chamber, interfaced to a 
Perkin Elmer (PE-Sciex, Thornhill, Toronto, Canada) API 300 triple quadrupole mass 
spectrometer operated in the multiple-reaction monitoring (MRM) mode. A 50 mm × 1.0 
mm, 3-µm Luna C18(2) reversed-phase column (Phenomenex Inc., Torrance, California) 
was installed in the instrument and was operated at 55ºC using a column heater (Fiatron 
CH-30, Milwaukee, Wisconsin). The isocratic mobile phase was composed of 75 % 
acetonitrile/25 % ammonium formate buffer (2 mM). The liquid chromatography 
separation was performed at 50°C with a flow rate of 0.05 mL/min. The total run time 
was 7 minutes.           
   
 The ion source (heated electrospray) used a turbo ionspray gas flowing at 6 L/min 
at 325°C. Nitrogen was used as the collision gas and the collision gas thickness was 
1.4×1014 molecules/cm2. Ionization was achieved in the positive mode using the 
following parameters: an ionization voltage of 4600 V and a ring voltage of 320 V; a 
collision energy of 31 V for the ammonium adduct ions and an orifice voltage of 31 V. 
The first quadrupole was set to select the ammonium adducts [M+NH4]
+ of Tac (m/z 
821.1) and ascomycin (m/z 809.6). The second quadrupole was used as a collision 
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chamber, and the third quadrupole was then used to select the characteristic product ions 
of Tac (m/z 576.1) and ascomycin (m/z 756.6). The retention times for Tac and 
ascomycin were 3.5 min. Following HPLC separation, the peak area corresponding to the 
MRM reaction (dwell time 150 ms) for Tac was measured relative to that of the MRM 
reaction (dwell time 150 ms) of the internal standard, ascomycin.  
      
  Peak area ratios obtained from MRM of the mass transitions for Tac (m/z 821.1 → 
576.1) and ascomycin (m/z 809.6 → 756.6) were used to calculate the concentrations of 
Tac by use of a calibration curve. This was generated from the analysis of a blank blood 
sample spiked with various amounts of Tac and fixed amounts of internal standard. 
                                
4.2.7. Data analysis                                                                                 
            
 The data analysis was carried out using a stepwise approach, according to a general 
approach suggested by Ette and Ludden (Ette and Ludden, 1995) with modifications: (1) 
determination of a basic PK model using the NONMEM program and obtaining the 
Bayesian individual parameter estimates, (2) selection of covariates using generalized 
additive modeling (GAM) and tree-based modeling (TBM), (3) final NONMEM 
modeling to determine the population PK model, and (4) evaluation of final population 
PK model using case-deletion diagnostics.  
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Step 1: Determination of basic PK model                
 
 Nonlinear mixed-effect models were used to characterize Tac population PK 
parameters from the whole blood concentration-time data using the NONMEM (version 
V; level 1.1; GloboMax LLC, Hanover, Md) with double precision. The first-order 
estimation method was used to derive population mean PK parameters, the intersubject 
variability (η) in these parameters, and residual variability between observed and 
predicted concentrations (∈). This model accounts for population parameter variability 
(between and within subjects) and residual variability (random effects), as well as 
parameter differences predicted by covariates (fixed effects).  
 
 One and two-compartment PK models with first-order absorption and elimination 
were tested. The one-compartment model was parameterized in terms of apparent CL 
(CL/F), apparent V (V/F) and ka. The two-compartment model was parameterized in 
terms of CL/F, volume of central compartment, intercompartmental CL, volume of 
peripheral compartment and ka. 
 
 Interindividual variability in CL/F was modeled using an exponential error model 
(Boeckmann et al., 1992) as shown in the equation below.     
       
(CL/F) j = TV(CL/F)∗(exp ηj , CL/F)      
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where CL/F j is the hypothetical true total body CL/F for the jth individual as predicted by 
the regression model. TV(CL/F) is the typical population value of CL/F. The ηj , CL/F is a 
random variable that represents the persistent difference between the jth individual’s 
CL/F and that predicted by the regression model and is assumed to be independent and 
normally distributed with zero mean and variance ω2. Interindividual variability in V/F is 
similarly modeled. 
 
 For residual variability, a series of error models was tested as follows:   
  
   C ij  = C pred, ij + ∈ ij         
   C ij  = C pred, ij ∗  (1 + ∈ ij  )      
   C ij  = C pred, ij ∗  (1 + ∈ ij , 1 ) + ∈ ij , 2      
    
where C ij  is the observed whole blood concentration and C pred, ij  is the corresponding 
model predicted value for the jth individual. ∈ ij , 1 and ∈ ij , 2  are random terms that are 
assumed to have 0 mean and variances  and , respectively. The variances ωσ12 σ22 2 and σ2 
were estimated as components of the population model.      
    
 With the fixed and random effects models chosen, empirical Bayes estimates of 
CL/F and V/F were obtained using the POSTHOC option within the NONMEM program. 
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Step 2: Selection of covariates        
            
 Stepwise GAM and TBM as implemented in Xpose3 (version 3.11) (Jonsson and 
Karlsson, 1999) running within the S-Plus (Version 2000; Insightful, Seattle, WA)  
program were performed on the empirical Bayesian parameter estimates for the selection 
of covariates which influence the PK parameters.   
  
 In the GAM analysis (Hastie and Tibshirani, 1990), the individual Bayes 
parameter estimates together with the covariates were entered in the analysis. At each 
step, individual covariates are added, deleted, or replaced in the regression model using 
Akaike’s information criterion (AIC) (Akaike, 1976) until a final model is obtained. The 
final model indicated a set of candidate covariates and its relationship i.e. linear or 
nonlinear, with each PK parameter. The GAM assumes the following general functional 
form: 
 
 Pi = α + f1(zi1) + f2(zi2) + …. + fn(zin) 
 
where pi is the ith individual’s parameter value, α is the intercept, zin is the ith 
individual’s value of the nth covariate and the f ( )s are linear or spline functions that 
relate the influence of the covariates to the parameter. The stepwise search is carried out 
according to a defined hierarchy (one for each covariate) of possible functional 
relationships, which for this analysis is: the covariate is not included in the model, the 
covariate is included in a linear fashion and the covariate is included in a nonlinear 
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fashion. The GAM approach provides for straightforward interpretation of results by 
assuming an additive structure. It also allows the contributions of various covariates to be 
displayed graphically. 
 
 Bootstrap in conjunction with GAM is run to assess the importance of the 
covariates and to give information about how covariates interact with respect to 
inclusion/exclusion from the covariate model. In bootstrap (Efron and Tibsgirani, 1993) 
of the GAM, the GAM is run a large number of times on bootstrap realizations of the 
original data set. The bootstrapped data sets are constructed by random sample with 
replacement from the original data set and the GAM is then run on each of them. The 
number of bootstrap iterations made in this study was 150. 
 
 TBM is an exploratory technique for uncovering structure in data, and assessing 
the adequacy of linear models (Breiman et al., 1984). A regression tree is built through a 
process known as binary recursive partitioning. The data are split into two parts, along 
with any of the X predictors (covariates), so that the resulting groups are most 
homogeneous with respect to the response. Specifically, all splitting points are examined 
along all predictors, and the one that produces the smallest total within-group variance in 
the two groups is chosen. The split at a node is that split on the X variables which most 
successfully separates the high response values from the low ones. The data are then split 
into two parts, and the process is repeated on each part. At each stage, all split points 
along all predictors are considered, so that the predictor can be used for splitting more 
than once. The splitting process can be terminated when no further splits can be found to 
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significantly improve the homogeneity of the subgroups. At this point, an unpruned tree 
has been “grown”. An unpruned tree usually includes too many split points compared to a 
situation where statistical significance check had been applied to each split.    
 
 Cross-validation is used to determine the appropriate tree size. First, the data set is 
divided into x number of groups, second, x number of trees are grown, each with one of 
the x groups omitted from the growth process and third, the fitted trees are used to predict 
the group of data not used to grow the tree. The improvement in the fit (measured by the 
deviance), at each node of the tree, is averaged over the x groups and the results are 
plotted. The improvement in fit will only continue up to a certain point after which the 
deviance will increase, i.e. the plot of the averaged deviance vs tree size will often exhibit 
a minimum at some point, which is the suggested optimal tree size. 
 
Step 3: Population model building using NONMEM 
  
 Each covariate screened as influential by the graphic explorations was entered into 
the population PK model derived in step 1. The continuous covariates were centered on 
their median values. In some cases, covariates not identified in step 2, yet bearing a 
logical relationship to a PK parameter, were also evaluated in the population model. 
  
 Depending on the nature of the covariate, a linear model for continuous variables or 
a step model for dichotomous variables was tested by stepwise addition to the basic 
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model as follows for TV(CL/F):        
  
TV(CL/F) = θ1 + θ2∗(covariate1 − median1)...    
TV(CL/F) = θ1+ θ3∗(covariate2)…      
  
where the θ’s are the parameters to be estimated. The covariate in the first equation is a 
continuous variable and the median is the corresponding median value of the population. 
The covariate in the second equation is a dichotomous variable. The covariates were 
entered in a similar manner for TV(V/F).       
    
 In the comparisons between hierarchical models, a likelihood ratio test was used. 
The ∆OBJF produced by the inclusion of a covariate is proportional to twice the negative 
log likelihood of the data and approximates a χ2 distribution with degrees of freedom 
equal to the difference in the number of parameters between the two models. A ∆OBJF of  
> 3.8 (P < 0.05) is chosen to represent statistical significance for the addition of one fixed 
effect. If a covariate was statistically significant, it was kept in the model and a new 
covariate was added and tested. If not, then the covariate was dropped from the model 
and the effect of another covariate was evaluated (step-up approach). The tentative final 
model was further tested by eliminating each covariate one at a time to evaluate the 
∆OBJF (step-down approach). Because of multiple comparisons, the level of significance 
for putting the covariate back in the model was set at ∆OBJF > 10.8 (p < 0.001, degree of 
freedom = 1). Only covariates that showed a significant contribution were preserved in 
the model. 
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 The model building process was also guided by various goodness-of-fit plots, 
residual analyses, the standard error of the parameters and changes to estimates of ω’s 
and σ resulting from changes to the model. Nonhierarchical models having equal 
numbers of parameters a ∆OBJF of 10 or more units were considered meaningful. The 
choice among models that exhibited similar overall goodness-of-fit characteristics was 
guided by parsimony and pragmatism. Parsimony is a principle that states that the 
simplest explanation that explains the greatest number of observations is preferred to 
more complex explanations. The parameters of the final model were re-estimated using 
the first-order conditional estimation (FOCE) in NONMEM.  
 
Evaluation of population PK parameters       
  
 Case deletion diagnostics or cross-validation was used to detect influential 
individuals and to explore the robustness of the model. Cross-validation was performed 
by refitting the selected model with one patient excluded one-at-a-time and the data 
reanalyzed by NONMEM using the final model. The new parameter values obtained 
from the single case-deleted data set were compared qualitatively with those from all 31 
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4.3. Results  
 
4.3.1. HPLC/MS/MS  assay                    
                                       
 Under the HPLC-electrospray-MS/MS operating conditions, the predominant 
precursor for Tac and ascomycin were the ammoniated ion [M+NH4]
+, m/z 821.1 and m/z 
809.6, respectively. Collision-induced fragmentation of these precursor ions gave the 
predominant product ions for Tac and ascomycin of m/z 576.1 [(M-210-H2O)H]
+ and m/z 
756.6 [(M-2H2O)H]
+, respectively. These mass transitions, m/z 821.1 → 576.1 and m/z 
809.6 → 756.6, were utilized for MRM. The fragmentation pathway of Tac leading to the 
elimination of 210 Da is shown in Figure 9.  
 
 Typical MRM chromatograms of (A) a Tac whole blood standard (0.25 ng/mL), (B) 
a Tac whole blood standard (100.0 ng/mL), (C) whole blood sample containing 25 ng/mL 
ascomycin (D) a whole blood sample obtained from a liver transplant patient containing 
40.3 ng/mL of Tac are illustrated in Figure 10. 
 
4.3.2. Calibration and validation        
  
 Linear calibration curves were obtained with correlation coefficients, r greater than 
0.99 (Figure 11); mean calibration curve parameters are reported in Table 13;  mean peak 
area ratios±s.d. of the whole blood, and  plasma calibration curves shown in Figure 11 are 
reported in Table 14. 
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          (M+NH4)
+ = 821.1 















































     
   
Figure 9. Fragmentation pathway of Tac leading to the loss of 210 Da.   
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A                          821.1/576.1
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C 809.6/756.6
































Figure 10. MRM chromatograms of (A) whole blood spiked with 0.25 ng/mL of Tac; (B) 
whole blood spiked with 100 ng/mL of Tac; (C) whole blood spiked with 25 ng/mL of 
ascomycin; and (D) clinical sample containing 40.3 ng/mL Tac. 
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The lower limit of quantification (LOQ) of Tac was assessed by pre-made whole blood / 
plasma samples. The LOQ was defined as the lowest concentration determined with an 
intra-day CV less than or equal to 20 % and with an accuracy of between 80 and 120 %, 
and was found to be 0.25 ng/mL for whole blood and plasma matrices (Table 15). Quality 
control samples, analysed in 6 replicates on 3 separate days, demonstrated acceptable 
inter-day variability of the system (Table 16). The absolute recovery is presented in Table 
17. The recoveries of Tac and ascomycin from whole blood were between 59.1 and 67.1 




Y = mx + b  
m 
(mean ± SD) (%CV) 
b 




(r ± SD)(%CV) 
 
Whole 
blood           
(n = 3) 
 
 
0.0228 ± 0.0034 
(14.9%) 
 
0.002 ± 0.009a 
(450%) 
 
0.9977 ± 0.0017 
(0.17%) 
 




0.0267 ± 0.0028 
(10.5%) 
 
0.014 ± 0.025b 
(178.6%) 
 
0.9955 ± 0.0033 
(0.33%) 
a  Statistically insignificant from 0 (p=0.7725). 
b  Statistically insignificant from 0 (p=0.4288).  
 
Table 13. Mean parameters of the calibration curves for Tac.  
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Table 14. Mean peak area ratios ± s.d. of the (A) whole blood, and (B) plasma calibration 
curves shown in Figure 11.  
 
 











Whole blood 0.25 0.29 ± 0.05 17.2 116.0 
 1.5 1.64 ± 0.23 14.0 109.3 
 15.0 15.15 ± 0.66 4.4 101.0 
 75.0 75.47 ± 1.38 1.8 100.6 
Plasma 0.25 0.29 ± 0.04 13.8 116.0 
 1.5 1.67 ± 0.21 10.8 111.3 
 7.5 7.10 ± 0.79 11.1 94.7 
 20.0 20.43 ± 1.32 6.46 102.2 
 
Table 15. Intra-day accuracy and precision for quantification of Tac in whole blood and 
plasma samples at different concentrations. 
 
    






Whole blood 1.5 15.0 
 15.0 9.3 
 75.0 2.0 
Plasma 1.5 14.2 
 7.5 13.3 
 20.0 8.3 
 
Table 16. Inter-day precision for Tac quantified in whole blood (n = 18) and plasma (n = 











(mean ± SD)(%) 
Tac 
 
1.5 60.6 ± 8.3 1.5 57.9 ± 4.1 
 
 
15.0 59.1 ± 10.0 7.5 69.1 ± 7.2 
 
 
75.0 67.1 ± 5.8 20.0 62.8 ± 5.6 
Ascomycin 
 
25.0 56.6 ± 5.4 25.0 55.5 ± 7.6 
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4.3.3. Patients and data collection 
         
 Data were collected prospectively from adult and paediatric liver transplant 
inpatients and outpatients who have been administered Tac at the National University 
Hospital, Singapore during the period from May 2001 to September 2003. Any such 
patients were eligible for recruitment into the study. Approval was obtained from the 
hospital’s ethics committee for the study. Informed verbal consent was obtained from the 
patients or their caregivers for blood sampling in addition to those required for routine 
TDM.  
 
 Adult inpatients were administered oral Tac as part of a triple immunosuppressive 
regimen that included basiliximab and corticosteroids whereas paediatric inpatients were 
administered oral Tac as part of a dual immunosuppressive regimen that included 
corticosteroids. The difference in Tac use (dual versus triple therapy) reflects the 
different prescribing patterns of Tac during clinical use in different patient groups by the 
prescribers. Thus the results of this study will be applicable clinically as it was derived 
from actual clinical data. Therapy was generally initiated at a dose of 0.05 mg/kg and 0.1 
mg/kg twice daily for adult and paediatric inpatients, respectively. Subsequent doses 
were adjusted empirically on the basis of clinical evidence of efficacy and toxicity and to 
maintain tacrolimus trough blood concentrations between 10 and 15 ng/mL in the first 
three months post-transplantation and between 5 and 10 ng/mL thereafter (Oellerich et 
al., 1998).  
 
    
  94  
 Serial blood samples were collected from adult and paediatric inpatients within a 
dosing interval of 12 hours in the immediate post-transplant period. For adult and 
paediatric outpatients, blood sampling was carried out during one of the outpatient visits 
for a duration of 2 to 6 hours. Only outpatients who had no changes in the doses of oral 
Tac for the past 1 week (steady-state) were included in the study. The exact dosing and 
sampling times were recorded on data collection forms, and this information was used in 
the analysis. Patient demographic and covariate data were obtained from the hospital’s 
patient medical records. One of the covariates investigated was the erythrocyte-to-plasma 
(E/P) ratio, i.e. the ratio of Tac concentration in the erythrocytes to that in plasma. The 
concentration (E) of Tac in the non-plasma, erythrocyte component of whole blood was 
calculated from the following relationship:  
 






where W and P are the concentrations of Tac in whole blood and plasma, respectively 
(Rowland and Tozer, 1994). 
  
 The dataset comprised a total of 213 whole blood Tac concentrations from 16 adult 
and 15 paediatric liver transplant patients. 182 plasma Tac concentrations were available 
for the determination of E/P ratio as some of the blood samples were haemolysed and 
some of the plasma samples were below the limit of quantification of the assay. Table 18 
lists the patient characteristics included in this study. There was a wide distribution of the 
patient covariates from childhood through to adulthood. The common indications for  
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 Covariate statistics 
Continuous covariates      
 
     Demography 
 
     AGE (yr) 
     WT (kg) 
     HT (m) 
     BSA (m2) 
 
     Laboratory measurements 
 
     APH (U/L) 
     ALT (U/L) 
     AST (U/L) 
     GGT (U/L) 
     LDH (U/L) 
     TOTBIL (µmol/L) 
     ALB (g/L) 
     TOTPRO (g/L) 
     Alpha-1-acid glycoprotein  
     (AAG) (mg/dL) 
     CREA (µmol/L) 
     UREA (mmol/L) 
     HCT (L/L) 





40.5 (1.41 – 67.0) 
55.0 (6.5 – 127) 
1.61 (0.72 – 1.76) 
1.55 (0.363 – 2.45) 
 
 
149 (37 – 718) 
152 (23 – 577) 
52 (15 – 236) 
147 (16 – 1249) 
731 (452 – 1453) 
21 (3 – 309) 
32 (24 – 44) 
62 (48 – 83) 
87.7 (42.1 – 192.2) 
 
60 (15 – 212) 
6.1 (1.4 – 42.4) 
31.1 (22.8 – 46.0) 
68 (12.2 – 147.1) 
Dichotomous covariates 
 
Gender (SEX): M / F 
RACE: Chinese / Malay / Indian 




23 / 8 
23 / 5 / 3 
15 / 16 
 
Table 18. Characteristics of patients (n = 31) included in the study. Values for 
continuous covariates are given as median (range). 
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liver transplantation were biliary atresia, hepatitis and alcoholic cirrhosis. Figure 12 
depicts the frequency distribution of whole blood samples by sampling time interval. 
 
4.3.4. Data analysis 
 
 A graph of the individual Tac concentrations versus time after dose is given in 
Figure 13. The disposition of Tac appeared to be adequately described by a one-
compartment model. Development of the structural PK model indicated that two-
compartment model with first order absorption does not significantly improve the 
description of the observed Tac concentration-time data compared to a linear, open one- 
compartment model (∆OBJF = 3.959). For ka, the inclusion of interindividual variability 
in the model does not result in a significant improvement. 
 
 For residual variance, the lowest OBJF of –1890.693 is produced by the combined 
additive and proportional error model, followed by the proportional error model (OBJF = 
-1864.931) and lastly the additive error model (OBJF = -1863.775). However, the CV 
associated with the estimation of the proportional portion of the combined additive and 
proportional error model is very high (i.e. 91.3 %). Thus, this residual error model is not 
selected for use and the proportional error model is selected instead.
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Observed whole blood Tac concentrations (DV) vs time after dose.
 
Figure 13. Observed whole blood Tac concentrations (DV) vs time after dose (TAD) 
plotted on a semilogarithmic scale. Data points are labeled by the ID number and each 
individuals data points are connected.  
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 A one-compartment PK model with first order absorption (subroutines ADVAN 2 
TRANS 2) is thus chosen as the basic structural model. At step 1, large interindividual 
variability was observed in CL/F (104.4 %) and V/F (113.1 %), suggesting that 
accounting for individual characteristics could reduce the variability and refine the 
predictive model. Basic goodness of fit plots for the basic structural sub-model of the 
population model are shown in Figure 14.  
 
 In step 2 of model development, the GAM analysis indicated that Tac CL/F is a 
linear function of WT, and V/F is a linear function of HT, CREA and HCT. Tables 19 
and 20 summarize the path taken to these models and show some of the other GAMs that 
are close to the best fit one. In each step, the term that results in the largest decrease in 
the AIC is added to the model. The residual sum of squares (RSS) and changes in RSS 
from the previous model are also shown. WT has the greatest influence on CL/F and it 
alone explains 35.6 % of the observed variability in CL/F. HT has the greatest influence 
on V/F, followed by CREA and HCT, accounting for 20.5 %, 19.4 %, and 14.9 % of the 
observed variability in V/F, respectively. The relationship between WT and Tac CL/F for  
the final GAM is shown in Figure 15. Figure 16 shows an Akaike plot for the GAM run 
for CL/F. The relationships between covariates and Tac V/F for the final GAM are shown 
in Figure 17. Figure 18 shows an Akaike plot for the GAM run for V/F. 
  
    











































































































































































































































































































































































































































































































Goodness of fit plots for basic population model.
 
Figure 14. Basic goodness of fit plots for the basic population model. The upper left panel shows the 
predictions for the typical individual in the population (PRED) vs the dependent variable (DV), i.e. the 
observed concentrations. The upper right panel is a plot of the individual predictions (IPRE) vs the 
dependent variable. The lower left is a plot of the absolute values of the individual weighted residuals 
(IWRE) vs the individual predictions. The lower right panel is a plot of the weighted residuals (WRES) vs 
the independent variable (TIME AFTER DOSE, TAD). In all but the lower left panel, each individual data 
points are connected by a line and labeled with the ID number. In the uppermost two panels, the solid line 
is the line of identity. In the lower left panel, the solid line is a smooth. 
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Step Term ∆RSS RSS AIC 
1 constant  1145.5 1221.9 
2          + WT -407.7 737.8 890.6 
 
 
Summary of models close to the minimum AIC model 
Equation AIC 
CL/F ~ WT 891 
CL/F ~ BSA 895 
CL/F ~ WT + HCT 918 
 
Table 19. The top part of the table shows the path taken to the final GAM for the CL/F of 
Tac, starting with the NULL model. In each step, the term that results in the largest 
decrease in the AIC is added (+) to the model. The bottom part of this table shows some 
models close to the final GAM (model with the smallest AIC value). The ~ in the 
notation of the models means “is a function of” and the + signs are to be interpreted 








Step Term ∆RSS RSS AIC 
1 constant  1773233 1891448 
2       + HT -362684 1410549 1646980 
3  + CREA -344668 1065881 1420527 
4       + HCT -263901 801980 1274842 
 
 
Summary of models close to the minimum AIC model 
Equation AIC 
V/F ~ HT + CREA + HCT 1270000 
V/F ~ HT + CREA + UREA + HCT 1360000 
V/F ~ ns(HT, df=2) + CREA + HCT 1362000 
 
Table 20. The top part of the table shows the path taken to the final GAM for the V/F of 
Tac, starting with the NULL model. In each step, the term that results in the largest 
decrease in the AIC is added (+) to the model. The bottom part of this table shows some 
models close to the final GAM (model with the smallest AIC value). The ~ in the 
notation of the models means “is a function of” and the + signs are to be interpreted 
figuratively and not literally. 
 
    











































GAM results  for CL/F.
 
Figure 15.  Results of GAM for CL/F. On the y-axis are the residuals from the GAM fit 








    




































Akaike plot of CL/F.
 
Figure 16. Results of GAM for CL/F, showing the Akaike plot of CL/F. On the y-axis 
are the models tested, with the best model at the bottom. The plus sign in some of the 
models indicates that the model tested consisted of the two terms, i.e. not addition. On the 




    





























































































































Figure 17.  Results of GAM for V/F. On the y-axes on each of the plots are the residuals 
from the GAM fit. On the x-axis of the uppermost plot is HCT-31.1. On the x-axis of the 
middle plot is CREA-60. On the x-axis of the lowermost plot is HT-1.61. 
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HT + CREA + HCT
HT + CREA + UREA + HCT
ns(HT, df = 2) + CREA + HCT
HT + CREA + HCT + EP
HT + ns(CREA, df = 2) + HCT
HT + AAG + CREA + HCT
HT + CREA + ns(HCT, df = 2)
HT + TBIL + CREA + HCT
HT + ALB + CREA + HCT
HT + TPRO + CREA + HCT
AGE + HT + CREA + HCT
HT + GGT + CREA + HCT
SEX + HT + CREA + HCT
HT + APH + CREA + HCT
HT + BSA + CREA + HCT
WT + HT + CREA + HCT
HT + HCT
HT + AAG + HCT
HT + TBIL + HCT
HT + UREA + HCT
ns(HT, df = 2) + HCT
HT + TPRO + HCT
HT + BSA + HCT
HT + HCT + EP
AGE + HT + HCT
WT + HT + HCT
HT + APH + HCT
HT + GGT + HCT
HT + ns(HCT, df = 2)
HT + ALB + HCT





Akaike plot of V/F.
 
Figure 18.  Results of GAM for V/F, showing the Akaike plot of V/F. On the y-axis are 
the models tested, with the best model at the bottom. The plus sign in some of the models 
indicates that the model tested consisted of the two terms, i.e. not addition. On the x-axis 
is the Akaike value, the lower the Akaike value, the better the fit. 
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 Bootstrap of the GAM for CL/F shows that WT has the highest relative inclusion 
frequency of 0.44 amongst the covariates investigated (Figure 19). The relative inclusion 
frequency was obtained by counting the number of times each covariate was selected by 
the GAM divided by the number of iterations. Therefore, the results derived from the 
bootstrap data supported the results from the original GAM analysis conducted with the 
actual patient data. It also shows that WT is indeed the most stable covariate relationship 
(Figure 20). Approximately 56 % of the 150 bootstrapped data sets had a covariate model 
size equal to two (Figure 21) in the final GAM model. To assess the adequacy of the 
number of bootstrapped data set used, a plot of the relative inclusion frequencies vs the 
bootstrap iterations is made (Figure 22). This plot shows that the frequency of inclusion 
of the covariates stabilizes after about 100 bootstrap iterations. Thus the use of 150 
bootstrap datasets in bootstrap of the GAM is suitable. 
 
 Bootstrap of the GAM for V/F shows that HCT, CREA and HT have the highest 
relative inclusion frequencies of 0.59, 0.53 and 0.48, respectively, amongst the covariates 
investigated (Figure 23). Therefore, the results derived from the bootstrap data supported 
the results from the original GAM analysis conducted with the actual patient data. It also 
shows that these three covariates are the most common three covariate combination 
(Figure 24). Approximately 66 % of the 150 bootstrapped data sets had a covariate model 
size equal to three (Figure 25) in the final GAM model. To assess the adequacy of the 
number of bootstrapped data set used, a plot of the relative inclusion frequencies vs the 
bootstrap iterations is made (Figure 26). This plot shows that the frequency of inclusion 
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of the covariates stabilizes after about 100 bootstrap iterations. Thus the use of 150 








0.0 0.2 0.4 0.6 0.8 1.0
Inclusion frequency
















0.0 0.2 0.4 0.6 0.8 1.0
Inclusion frequency
(A) Total frequency of covariates for CL/F.
 
 
Figure 19.  Results of bootstrap of the GAM for CL/F, showing (A) Total frequency of 
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Figure 20.  Results of bootstrap of the GAM for CL/F, showing the most common one to 
four covariate combinations for CL/F. The y-axes shows the covariate combinations and 
the x-axes the relative inclusion frequency, i.e. the number of times the combination was 
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Stability of inclusion probability of covariates for CL/F.
 
Figure 22.  Results of bootstrap of the GAM for CL/F, showing stability of inclusion 
probability of covariates for CL/F. 
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Figure 23.  Results of bootstrap of the GAM for V/F, showing (A) Total frequency of 
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Figure 24.  Results of bootstrap of the GAM for V/F, showing the most common 
covariate combinations for V/F. The y-axes shows the covariate combinations and the x-
axes the relative inclusion frequency, i.e. the number of times the combination was found 
divided by the number of iterations (150). 
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Model size distribution for V/F.
 
Figure 25.  Results of bootstrap of the GAM for V/F, showing the model size distribution 
for V/F. 
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Stability of inclusion probability of covariates for V/F.
Figure 26.  Results of bootstrap of the GAM for V/F, showing the stability of inclusion   
probability of covariates for V/F. 
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 For TBM, the “unpruned” regression tree (size 5) for CL/F is shown in Figure 27. 
Cross validation studies show an optimal tree size of 3 for this regression tree (Figure 
28). The “pruned” tree of size 3 for CL/F is shown in Figure 29, which shows that WT 
and HCT are the predictors of CL/F. The first and second nodes for splitting the data 
occurred at WT of 25.2 kg and HCT of 32.3 L/L, respectively. 
 
 For TBM, the “unpruned” regression tree (size 4) for V/F is shown in Figure 30. 
Cross validation studies show an optimal tree size of 2 for this regression tree (Figure 
31). The “pruned” tree of size 2 for V/F is shown in Figure 32, which shows that HT is 
the most significant predictor of V/F. The node for splitting the data occurred at HT of 
1.625 m. 
 
 The results of the hypothesis testing on the covariates using NONMEM are 
summarized in Table 21. APH was included in the covariate model for CL/F as a discrete 
covariate with 200 U/L as the cut-off value instead of a continuous variable, because it 
produced better parameter estimates in the model. Table 22 summarizes the ∆OBJF when 
each of the Θs of the covariates appearing in the final NONMEM model is set to zero, 
showing the significance of each of the parameters (a ∆OBJF > 10.8 is significant with p 
< 0.001). A comparison of the covariates selected by the different regression methods and 
NONMEM is given in Table 23. From this table, it can be seen that there was no uniform 
agreement in the covariate sets selected by the regression methods and NONMEM. 
However, WT was consistently selected for the covariate model for CL/F while HT was 
consistently selected for the covariate model for V/F by the three methods. 
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A tree-based model ("unpruned") for CL/F.
 
Figure 27.  Regression tree (“unpruned”) of CL/F. The partitioning variable and its value 
are presented above to each split. The length of each branch is proportional to the 
importance of the split. At the terminal leaves, the predicted values of the dependent 
variable are displayed. 
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Figure 28.  Results from exploring the optimal tree size using cross-validation. On the y-
axes are the deviances and on the x-axes are the corresponding tree sizes. 
 
 
    





A tree-based model ("pruned") for CL/F.
 
Figure 29.  Regression tree (“pruned”, size 3) of CL/F. The partitioning variable and its 
value are presented above to each split. The length of each branch is proportional to the 
importance of the split. At the terminal leaves, the predicted values of the dependent 
variable are displayed. 
    








A tree-based model ("unpruned") for V/F.
 
Figure 30.  Regression tree (“unpruned”) of V/F. The partitioning variable and its value 
are presented above to each split. The length of each branch is proportional to the 
importance of the split. At the terminal leaves, the predicted values of the dependent 
variable are displayed. 
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Tree size exploration for V/F.
 
Figure 31.  Results from exploring the optimal tree size using cross-validation. On the y-
axes are the deviances and on the x-axes are the corresponding tree sizes. 
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| HT<1.625
103.1 369.1
A tree-based model ("pruned") for V/F.
 
Figure 32.  Regression tree (“pruned”, size 2) of V/F. The partitioning variable and its 
value are presented above to each split. The length of each branch is proportional to the 
importance of the split. At the terminal leaves, the predicted values of the dependent 
variable are displayed.   
    
       
                   




Hypothesis tests OBJF ∆OBJF   Ref. p-value
[1] CL/F, V/F, ka -1864.931    
[2]      CL/F=F(WT) -1966.314 101.383 vs. [1] <0.001
[3] CL/F=F(WT), V/F=(HCT) -1973.465 7.151 vs. [2] <0.01 
[4] CL/F=F(WT), V/F=(HCT, HT) -2009.909 36.444 vs. [3] <0.001 
[5] CL/F=F(WT, APH), V/F=(HCT, HT) -2026.264 16.355 vs. [4] <0.001 
[6] CL/F=F(WT, APH, CREA), V/F=(HCT, HT) -2038.14 11.876 vs. [5] <0.001b 
aExponential intersubject variability for structural PK parameters of CL/F and V/F. 
bFinal model.
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CL/F model V/F model 
Covariate ∆OBJF Covariate ∆OBJF 
WT 41.991 HT 36.705 
APH 12.406 HCT 26.024 
CREA 11.876   
 
Table 22. ∆OBJF when each of the Θs of the covariates appearing in the final 





 Regression methods  
Parameter GAM TBM NONMEM 
CL/F ~ WT ~ WT + HCT ~ WT + APH + CREA 
V/F ~ HT + CREA + HCT ~ HT ~ HT + HCT 
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 Final population PK model of Tac in Asian adult and paediatric liver transplant 
patients and its parameters estimated using first-order (FO) and FOCE with interaction 
are shown in Tables 24 and 25, respectively. From the results, it can be seen that the 
parameter estimates derived from the two methods of estimation were similar. Strong 
trends were absent in the basic goodness-of-fit plots for the final population model as 
shown in Figure 33, and indicated a reasonable model fit to the observed data. WRES vs 
PRED for the final population PK model is shown in Figure 34. The etas (random 
parameters) associated with the final model are normally distributed with mean of zero 
(Figure 35). Figure 36 illustrates the whole blood concentration-time profiles for two 
typical subjects together with the predicted concentrations arising from the population 
and the ‘posthoc’ individual parameter estimates. 
 
 The typical absorption rate constant, ka, was 2.08 hr 
–1, which corresponds to a 
population mean first-order absorption half-life, tabs, of 0.33 hr (derived from the 
expression, tabs = 0.693 ÷ ka). The population mean first-order elimination constant, k, 





) and the 
corresponding population mean t½ is 10.7 hr (derived from the expression, t½ = 0.693 ÷ 
k). The population mean time to maximum blood concentration (tmax) was 1.72 hr, 









    
       
                    
Table 24.  Final population PK model of Tac in Asian adult and paediatric liver transplant patients and its parameters. 
                     Parameter 
 
Symbol        Units Estimated 
value 
Precision of estimation 
Std. error          CV (%)   
CL/F 
CLΘ  L/hr 14.1 1.93  13.7
V/F 
VΘ  L 217   
   
   
   
   
   
   
   
   
 






Θ  hr-1 2.08 0.292 14.0
Factor for WT on CL/F WT
CLΘ  L.hr-1kg-1 0.237 0.0517 21.8
Factor for APH ≥ 200 U/L on CL/F APH
CLΘ  L/hr -2.93 1.17 39.9
Factor for CREA on CL/F CREA
CLΘ  L2.hr-1.µmol-1 -0.0801 0.0357 44.6
Factor for HCT on V/F HCT
VΘ  L2/L -7.83 3.59 45.8
Factor for HT on V/F HT
VΘ  L/m 179 37.3 20.8
Interpatient variance of CL/Fj about CL/FTV ω2CL/F 0.432 0.159 36.8
Interpatient variance of V/Fj about V/FTV ω2V/F 0.407 0.195
 
47.9
 CV of CL/Fj about CL/FTV CVCL/F % 65.7 
CV of V/Fj about V/FTV CVV/F % 63.8 
Intrapatient variance of Cij about Cpred, ij σ2 0.121 0.0321
 
 26.5
 CV of Cij about Cpred, ij σ % 34.8 
Structural models:  TV(CL/F) =  + *CLΘ WTCLΘ  (WT – 55) +  * Y + * (CREA-60)    APHCLΘ CREACLΘ
    TV(V/ = V + *F) 
K
Θ HCTVΘ  (HCT – 31.1) + * (HT-1.61) HTVΘ
    TV a = 
ak
 Θ
 Random effects models:  CL/Fj = TV(CL/F) * exp ( ηj, CL ) 
    V/Fj = TV(V/F) * exp ( ηj, V ) 
    Cij = Cpred, ij  ∗ (1 + εij) 
where, WT = weight in kg; APH = alkaline phosphatase in U/L; CREA = creatinine in µmol/L; HCT = haematocrit in L/L; HT = height in m; TV(CL/F) = 
typical population value for CL/F; TV(V/F) = typical population value for V/F; and the value of Y is 0 for APH < 200 U/L. The Y value for APH ≥ 200 U/L 
is 1.   
 
        125  
       
                    
Table 25.  Final population PK model of Tac in Asian liver transplant patients and its parameters estimated using FOCE. 
                     Parameter 
 
Symbol        Units Estimated 
value 
Precision of estimation 
Std. error          CV (%)   
CL/F 
CLΘ  L/hr 19.5  3.2 16.4
V/F 
VΘ  L 267   
   
   
   
   
   
   
  
   
 






Θ  hr-1 1.67 0.311 18.6
Factor for WT on CL/F WT
CLΘ  L.hr-1kg-1 0.331 0.0914 27.6
Factor for APH ≥ 200 U/L on CL/F APH
CLΘ  L/hr -3.91 1.28 32.7
Factor for CREA on CL/F CREA
CLΘ  L2.hr-1.µmol-1 -0.0549 0.0354 64.5
Factor for HCT on V/F HCT
VΘ  L2/L -9.99 3.53 35.3
Factor for HT on V/F HT
VΘ  L/m 241 52 21.6
Interpatient variance of CL/Fj about CL/FTV ω2CL/F 0.361 0.0614 17.0
Interpatient variance of V/Fj about V/FTV ω2V/F 0.418 0.131
 
31.3
 CV of CL/Fj about CL/FTV CVCL/F % 60.1 
CV of V/Fj about V/FTV CVV/F % 64.7 
Intrapatient variance of Cij about Cpred, ij σ2 0.145 0.0304
 
 21.0
 CV of Cij about Cpred, ij σ % 38.1 
Structural models:  TV(CL/F) =  + *CLΘ WTCLΘ  (WT – 55) +  * Y + * (CREA-60)    APHCLΘ CREACLΘ
    TV(V/ = V + *F) 
K
Θ HCTVΘ  (HCT – 31.1) + * (HT-1.61) HTVΘ
    TV a = 
ak
 Θ
 Random effects models:  CL/Fj = TV(CL/F) * exp ( ηj, CL ) 
    V/Fj = TV(V/F) * exp ( ηj, V ) 
    Cij = Cpred, ij  ∗ (1 + εij) 
where, WT = weight in kg; APH = alkaline phosphatase in U/L; CREA = creatinine in µmol/L; HCT = haematocrit in L/L; HT = height in m; TV(CL/F) = 
typical population value for CL/F; TV(V/F) = typical population value for V/F; and the value of Y is 0 for APH < 200 U/L. The Y value for APH ≥ 200 U/L 
is 1.   
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Goodness of fit plots for final population model.
 
 
Figure 33. Basic goodness of fit plots for the final population model. The upper left panel shows the 
predictions for the typical individual in the population (PRED) vs the dependent variable (DV), i.e. the 
observed concentrations. The upper right panel is a plot of the individual predictions (IPRE) vs the 
dependent variable. The lower left is a plot of the absolute values of the individual weighted residuals 
(IWRE) vs the individual predictions. The lower right panel is a plot of the weighted residuals (WRES) vs 
the independent variable (TIME AFTER DOSE, TAD). In all but the lower left panel, each individual data 
points are connected by a line and labeled with the ID number. In the uppermost two panels, the solid line 
is the line of identity. In the lower left panel, the solid line is a smooth. 
 
    




















































































































































































































WRES vs PRED for the final model.
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Figure 35. Histogram with density line plots showing the distribution of (A) ETA1; and 
(B) ETA2 of the final model. 
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Figure 36. Whole blood Tac concentration-time profiles from (A) a 14 year old male 
paediatric patient; and (B) a 60 year old male adult patient, showing measured (●), 
population predicted (▲) and individual predicted (■) concentrations from the full 
population PK model for Tac. 
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 CL/F for a representative patient, weighing 55 kg, APH < 200 U/L and CREA 60 
µmol/L, was 14.1 L/hr. CL/F increased by 0.237 L/hr per kg WT; hence a 1-kg increase 
in body weight resulted in a 1.7 % increase in CL/F. CL/F decreased by 2.93 L/hr when 
APH ≥ 200 U/L; therefore APH ≥ 200 U/L was associated with a 20.8 % reduction in 
CL/F. CL/F decreased by 0.0801 L/hr per µmol/L increase in CREA; hence 1 µmol/L 
increase in CREA was associated with a 0.6 % reduction in CL/F.       
 
 V/F for a representative patient, of HT 1.61 m and HCT of 31.1 L/L, was 217 L. 
V/F decreased by 7.83 L per 1 L/L increase in HCT; hence a 1 L/L increase in HCT was 
associated with a 3.6 % reduction in V/F. V/F increased by 179 L per m in HT; therefore 
every 1 m increase in HT was associated with a 82.5 % increase in V/F.  
 
 The population mean CL/F of 14.1 or 19.5 L/hr obtained in this study can be 
compared with that obtained in the first study involving the paediatric patients which has 
a mean population value of 7.41 L/hr. Thus, it can be seen that the CL/F estimated in the 
second study, has a value that is about twice that of the first study. Also, the population 
mean V/F of 217 or 267 L obtained in this study has a higher value than the value of 198 
L obtained in the first study. Possible reasons for the difference in the values of these 
estimates include differences in the patient composition and the difference in the 
analytical methods used for quantification of tacrolimus in these two studies. 
 
 Case deletion diagnostics for the 30 single case-deleted reanalyses of the final 
model are given in Table 26. CVs for parameter estimates from each reanalysis were less 
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than 15 % for all parameters. Using the population PK model derived in this study, values 
of covariates WT and HT (Leung et al., 1996; Epidemiology and Disease Control 
Department, 1998; Franklin, 1999), CREA (Jury, 1979) and HCT (McPherson et al., 
1978; Yip  et al., 1984) were obtained from the literature to be used for the calculation of 
CL/F and V/F for male patients of the ages 3 to 60 years old. These PK parameters were 
then used for the calculation of WT-normalized CL/F, V/F and doses needed to achieve a 
desired steady-state whole blood trough concentration of 10 ng/mL for male patients of 
the ages between 3 to 60 years old. Graphical plots of these results are shown in Figures 
37, 38 and 39.  
 
Table 26. Case deletion diagnostics for evaluation of final model estimates. 
Parameter Mean CV(%) Minimuma Maximuma 
CLΘ  14.15 3.27 13.3 15.3 
VΘ  217.68 4.73 194 243 
ak
Θ  2.09 3.59 1.98 2.35 
WT
CLΘ  0.238 5.02 0.202 0.264 
HCT
VΘ  -7.93 13.1 -10.5 -4.9 
HT
VΘ  180.16 6.82 152 227 
APH
CLΘ  -2.95 11.7 -4.2 -2.19 
CREA
CLΘ  -0.0799 14.2 -0.103 -0.0367 
aMinimum and maximum values of all 30 estimates (each from one case deletion   
re-run of final model). 
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Figure 37. Relationships between (A) age and CL/F; and (B) age and WT-normalized 
CL/F. Solid line is a spline smooth. 
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Figure 38. Relationships between (A) age and V/F; and (B) age and WT-normalized V/F. 
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Figure 39. Relationship between age and WT-normalized dose needed to achieve a 
desired steady-state whole blood trough concentration of 10 ng/mL. Solid line is a spline 
smooth. 
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4.4. Discussion 
 
 Using population techniques, a detailed PK analysis of Tac was performed in Asian 
adult and paediatric liver transplant patients. Such techniques are able to analyze sparse 
and dense data sets, quantitatively assess the influence of patient covariates on drug 
disposition, and ultimately provide dosing regimen algorithms for optimal individualised  
dosing (Whiting et al., 1986; Ludden, 1988).  
 
 In this study, we estimated Tac PK parameters in conjunction with common clinical 
covariates to build a model to predict individual Tac CL/F and V/F that may be used in 
the clinical setting to estimate dose requirements. The mean population ka of 2.08 hr 
-1 
determined in this study is about half compared to 4.48 hr –1, a value which was reported 
in a previous study (Jusko et al., 1995a). After oral administration, Tac was absorbed 
quickly with a mean tmax of 1.72 hr. This is similar to the mean tmax of 2.1 hr reported in a 
study in paediatric liver transplant patients (Wallemacq et al., 1998). 
 
 We found a Tac PK population estimate of CL/F of 14.1 L/hr. For a representative 
paediatric patient (WT 18.4 kg, CREA 32.7 µmol/L, APH 166 U/L, HT 0.95 m and HCT 
31.7 L/L) in this study, the calculated CL/F is 0.414 L/hr/kg or 7.62 L/hr. This is about 
twice the value of CL/F estimates of 0.21 L/hr/kg (estimated for a 15 kg patient when 
time after treatment initiation = 0, bilirubin = 0.6 mg/dL and normal ALT) reported 
following oral administration of Tac to paediatric liver transplant recipients being 
converted from cyclosporin to Tac (Sanchez et al., 2001). This is also similar to the 
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population mean CL/F estimate of 5.75 L/hr obtained in paediatric cut-down liver 
transplant recipients (Staatz et al., 2001). For a representative adult patient (WT 67.2 kg, 
CREA 98 µmol/L, APH 126 U/L, HT 1.66 m and HCT 34.7 L/L) in this study, the 
calculated CL/F is 0.208 L/hr/kg. This is similar to CL/F estimates of 0.25 L/hr/kg 
reported following oral administration of 5 mg Tac to caucasian subjects (Mancinelli et 
al., 2001). As the two studies (Mancinelli et al., 2001; Sanchez et al., 2001) were 
performed on Caucasian patients, it appears that race does not have an effect on the CL/F 
of Tac because the population mean values of CL/F of these patients are comparable to 
that in Asian patients of similar age groups as determined in our study.  
 
 Part of the interindividual variability in the CL/F of Tac was explained by WT, 
elevated APH and serum CREA of the patient. The interindividual variability of CL/F in 
the basic model was 104.4 %; however, on including the patient’s body WT, APH level 
and CREA, this variability is reduced to 65.7 % in the final population model. Thus, the 
CL/F of Tac is influenced by three factors: the body size, liver function and renal 
function.  
 
 The covariate submodel for CL/F has the greatest importance because of its 
possible role in dosage regimen design. GAM, TBM and NONMEM all showed that WT 
is the most important covariate influencing CL/F of Tac. Specifically, a 1-kg increase in 
body WT resulted in a 1.7 % increase in CL/F. Hence, at two extremes of weight, average 
45 kg and 80 kg patients (with normal APH and CREA 60 µmol/L) would have CL/F of 
11.7 L/hr and 20.0 L/hr, respectively. Hence, dose adjustment of Tac for WT appears 
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necessary. This finding is of particular clinical relevance because it indicates that dosing 
on a mg per kg basis would decrease the variability in concentration-time profiles of Tac 
into a narrower range for the paediatric and adult Asian liver transplant patients. 
Therefore, the current practice of dosing of oral Tac by WT is justified in liver transplant 
patients.  
 
 In this study it has been found that a rise in APH ≥ 200 U/L was independently 
associated with a reduction in Tac CL/F of 2.93 L/hr. APH, a variable which reflects 
hepatocellular alterations and biliary excretion, was found to have an effect on CL/F, but 
only when it is incorporated into the model as a discrete variable with a cut-off value of 
200 U/L. Tac is primarily metabolized in the liver and intestinal mucosa by the 
cytochrome P4503A4 enzyme, and eliminated through biliary excretion. Therefore, 
patients with poor liver function will have reduced Tac CL/F as compared with patients 
with normal liver function. This is consistent with the results of previous studies in adult 
liver transplant patients, which reported that hepatic dysfunction can decrease Tac CL 
and increase t½  (Jain et al., 1990; Jain et al., 1993). 
 
 Serum CREA has been found to influence the CL/F of Tac in this study. 
Specifically, a 1-µmol/L increase in CREA was associated with a 0.6 % reduction in 
CL/F of Tac. Hence, at two extremes of CREA, patients with 60 µmol/L and 120 µmol/L 
(with normal APH and WT 55 kg) would have CL/F of 14.1 L/hr and 9.3 L/hr, 
respectively. Hence, dose adjustment of Tac for CREA appears unnecessary. Renal CL of 
Tac is less than 1 % of total body CL (Venkataramanan et al., 1991). Therefore the 
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influence of CREA on Tac CL/F is unlikely to be a reduction in renal CL. Results from 
previous studies of the influence on renal function on the CL of Tac have been 
contradictory. Some studies reported no significant correlation between serum CREA 
concentration and CL of Tac (Gruber et al., 1994; Staatz et al., 2003) while other studies 
have found such a correlation. The results of a study showed that a rise in CREA ≥ 2 
mg/dL was independently associated with a 40 % reduction in Tac CL in hematopoietic 
cell transplant patients (Jacobson et al., 2001). The authors hypothesized that a high 
CREA may serve as a surrogate of altered renal blood flow resulting from subclinical 
hepatic injury. A study  reported that the CL of recipients with renal dysfunction, which 
was defined as serum CREA over 1 mg/dL, was 80.9 % of that in recipients with serum 
CREA below this level (Fukatsu et al., 2001). The findings were hypothesized to be due 
to alterations in drug metabolism related to the hepatorenal syndrome. The conflicting 
results of the influence of CREA on CL/F of Tac in the different studies may be due to 
the different ranges of CREA encountered in the patients of the different studies.  
 
 A study in rats showed that the F of Tac was increased by about 35 % in cisplatin-
induced acute renal failure rats (Okabe et al., 2000). This was due to two mechanisms: 
impaired hepatic metabolism of Tac during renal dysfunction, and increased absorption 
rate of Tac in the intestine of rats with renal dysfunction, which leads to a partial 
saturation of hepatic extraction (Okabe et al., 2002). Therefore, although renal failure is 
commonly thought to affect only the renal elimination of drugs, it may have different 
influences on the PK of a drug (Gibson, 1986). Thus, impaired hepatic metabolism and 
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increased F are possible mechanisms explaining the effect of renal dysfunction on CL/F 
of Tac in humans as observed in this study. 
  
 The following example illustrates how the covariate sub-model for CL/F of Tac 
may be used in the clinical setting: A 60 kg adult with an APH of 160 U/L and CREA of 
80 µmol/L will have an estimated CL/F of: CL/F (L/hr) = population CL/F estimate + 
0.237*(WT-55) − 2.93 − 0.0801*(CREA-60) = 14.1 + 1.185 − 2.93 − 1.602 = 10.8. 
 
 The population estimate of V/F of 217 L is reasonable for a highly lipophilic 
compound like Tac. For a representative paediatric patient (WT 18.4 kg, CREA 32.7 
µmol/L, APH 166 U/L, HT 0.95 m and HCT 31.7 L/L) in this study, the calculated V/F is 
94.2 L (5.12 L/kg). This is similar to V/F of 9.0 L/kg reported following oral 
administration of Tac to paediatric liver transplant recipients (Wallemacq et al., 1998). 
For a representative adult patient (WT 67.2 kg, CREA 98 µmol/L, APH 126 U/L, HT 
1.66 m and HCT 34.7 L/L) in this study, the calculated V/F is 198 L (2.94 L/kg). This is 
about half of the V/F estimate of 399 L reported following oral administration of Tac to 
adult liver transplant recipients (Staatz et al., 2003). As the two studies (Wallemacq et 
al., 1998; Staatz et al., 2003) were performed in Caucasian patients, it appears that race 
does not have an effect on the V/F of Tac because the population mean values of V/F of 
these patients are comparable to that in Asian patients of similar age groups as 
determined in our study.  
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 Part of the interindividual variability in the V/F of Tac was explained by HT and 
HCT of the patient. The interindividual variability of V/F in the basic model was 113.1 
%; however, on including the patient’s HT and HCT, this variability is reduced to 63.8 % 
in the final population model. Thus, the V/F of Tac is affected by two factors: the body 
size and HCT. HT has been found to be a better indicator of body size and hence drug 
distributional space than WT, AGE and BSA in this group of patients. Our previous work 
of the population PK of Tac in Asian paediatric liver transplant patients showed that BSA 
correlates with the V of Tac. There was a negative association of HCT with V/F of Tac, 
which is a previously unreported finding. It supports our previous hypothesis made in the 
previous study of this thesis, regarding the effect of haematocrit on the V of Tac, based 
on the phenomenon that Tac is highly bound to red blood cells (Nagase et al., 1994). 
Therefore, an increase in HCT would decrease the partitioning of Tac into fat, thereby 
decreasing its V. 
 
 The following example illustrates how the covariate sub-model for V/F of Tac may 
be used in the clinical setting: A 1.65 m adult with a haematocrit of 35 L/L will have an 
estimated V/F of: V/F (L) = population V/F estimate – 7.83*(HCT-31.1) + 179*(HT-1.61) 
= 217 – 30.5 + 7.16 = 193.7. 
 
 Once the approximate Tac CL/F and V/F of an individual is known, an estimate of 
the dose needed to achieve a desired steady-state whole blood trough concentration is 
possible using the following equation: 
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where CSS, min  is the desired steady-state whole blood trough concentration, k is 
elimination rate constant and τ is the dosing interval. The mean population PK 
parameters provided by the population model derived in this study may be useful in TDM 
for the estimation of an individual’s PK parameters by using Bayesian methods, which 
require prior information about population kinetic parameters of the population. 
 
 Among other PK parameters estimated in this study, the t½ is of importance for the 
clinical use of any drug and it should be considered. Figure 40 shows that the t½ of Tac is 
inversely proportional to CL/F and is not influenced by V/F. Thus, any factor reducing 
CL/F (e.g. reduced WT and elevated APH or CREA) will prolong the t½ of Tac. The 
mean population t½ of 10.7 hr derived in this study is similar to the mean t½ of 12.1 hr 
reported in one study (Jusko et al., 1995a). 
 
  The current population model for Tac has appreciably reduced interpatient 
variabilities in CL/F and V/F. It can be further seen that the patient covariates identified 
in this model have a large impact on dosage regimen design (Figure 41) in which wide 
range of doses were required to achieve a target steady-state trough concentration of 10 
ng/mL.  
 
 The population PK analysis using NONMEM also estimated interindividual and 
residual variabilities in addition to mean PK parameters. Reasonably large interindividual  
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Figure 40. Individual estimates obtained for the t½ in all patients included in the dataset 
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Figure 41. Model-predicted Tac doses (mg/kg/12hr) required to reach a target steady-
state trough concentration of 10 ng/ml in (A) 15 paediatric patients; and (B) 16 adult 
patients. 
    
  145  
variabilities of 65.7 % and 63.8 % were estimated for CL/F and V/F, respectively. This 
may be because each of these parameters (i.e. CL/F and V/F) is a composite of two 
parameters. Thus the interindividual variabilities estimated are the result of 
interindividual variabilities in CL or V in addition to F. Interindividual variabilities in F 
of Tac have been reported to be 63.0 % (Fukatsu et al., 2001) and 21.0 % (Yasuhara et 
al., 1995) in Japanese adult and paediatric liver transplant patients, respectively. 
Reasonably moderate residual variability of 34.8 % was estimated. 
 
 It can be seen that the weight-normalized dose decreases steadily from a value of 
0.092 mg/kg/12 hr at an age of 3 years to a value of 0.05 mg/kg/12 hr at an age of 19 
years and remains constant until an age of 60 years. This shows that paediatric patients 
require about twice as much of the weight-normalized dose compared to adult patients to 
maintain the same steady-state whole blood trough concentrations, an observation which 
is consistent with that reported in the literature (McDiarmid et al., 1993). It also shows 
that the population PK model derived in this study is able to offer an accurate prediction 
of a clinically observed phenomenon. 
 
Information derived from this population model may subsequently be used for 
dosage individualization through Bayesian forecasting (Thomson and Whiting, 1992).  
Bayesian estimation uses prior parameter probability distributions, together with the 
patient’s measured serum concentration(s), to arrive at values for the PK parameters that 
are most likely to represent the patient’s true values when data are sparse. PK parameters 
for each patient become individualized and the influence of the population parameters 
    
  146  
decreases(Fernandez de Gatta et al., 1996). Optimally, these techniques also inform the 
clinician of the next appropriate dose to administer in order to maintain or reach a desired 
concentration. The number of blood collections needed and the time to reach the required 
drug concentrations can be reduced. The advantage of Bayesian modeling is that the 
presence of the a priori population estimates restricts the newly estimated parameter 
values so that they are less likely to give odd combinations that simply happen to fit the 
data. Therefore, ultimately, a population model for Tac in conjunction with Bayesian 
forecasting may lead to drug-dosing algorithms that can individualize a patient’s dose, 
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5. Conclusions 
  
 The clinical PK of Tac was investigated in Asian paediatric and adult liver 
transplant patients using the population approach, which is the focus of this research 
work. Population methods are particularly appropriate in these patients because they 
allow the modeling of PK responses in a relatively large group of patients with sparse 
data obtained during routine TDM. Moreover, population models would offer the 
possibility of better dosage individualization, both ‘a priori’ and ‘a posteriori’, using 
Bayesian forecasting. If a patient has not yet received a drug, Bayesian forecasting can 
provide an initial dosage recommendation based on population values. However, if drug 
concentrations are available through TDM, they can be used as feedback and the 
Bayesian program will provide new recommendations based on both population and 
patient-specific values. As more drug levels are used as feedback, the forecasted doses 
will shift towards patient-specific values and less population-based. 
 
 For the second study in this thesis, it is the first report of Tac population PK study 
which included both adult and paediatric Asian liver transplant patients. PK parameters 
derived in the two studies were comparable to those reported in earlier studies on subjects 
of similar ages (Wallemacq et al., 1998; Mancinelli et al., 2001; Sanchez et al., 2001; 
Staatz et al., 2003). Several patient characteristics, which have significant influence on 
the PK parameters of Tac have been identified and their relationships to the PK 
parameters elucidated. These patient covariates have explained a large portion of the 
interindividual variabilities in the PK parameters of Tac upon inclusion into the 
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population models. Future studies are necessary involving more covariates so as to 
explain a larger portion of the interindividual variabilities in the PK parameters of Tac. 
 
 The results of this study show that the PK parameters of Tac are influenced by the 
developmental characteristics and clinical conditions of the patient. As liver and renal 
functions of the patient are factors affecting the PK of Tac, these should be routinely 
monitored. This is especially critical in the early post-transplant period in which 
pathophysiological changes can occur rapidly in the transplant patients. Tac 
concentrations falling outside the therapeutic range may result in toxicity or therapeutic 
failures; therefore, rapid adjustment of doses is imperative.  
 
 The results of the study support the current clinical practice of dosing oral Tac by 
the patient‘s body WT. Given these findings, the mean population PK parameters can be 
estimated and then applied to compute dosages of Tac in Asian adult and paediatric liver 
transplant patients. However, these should be applied with caution because of the 
unexplained variability in the PK parameters. Therefore, a close monitoring of Tac whole 
blood concentrations, especially during the first month of transplantation, is 
recommended. Furthermore, although the patients included in the two studies are 
representative of the general Asian liver transplant population, it is insufficient for 
establishing a definitive model for dose recommendation for these patients and other 
patients of non-Asian origins. Thus, it represents the limitation of the work in this thesis. 
This is because there are only a limited number of liver transplants performed locally. For 
example, there were only 46 cases of liver transplants performed in Singapore between 
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1995 and 1999 (Wai et al., 2000). Thus future studies involving larger numbers of 
patients will be necessary to confirm the present findings.  
 
 The patient groups included in the two studies are representative of “real-life” 
Asian liver transplant recipients. The dosages of Tac given to different subjects (and also 
during the course of each patient’s therapy) varied considerably. The data collected in the 
two studies characterized that which is normally available for transplant patients. Thus 
findings from this thesis such as the mean population pharmacokinetic estimates should 
be applicable to the larger Asian liver transplant community. 
 
 Finally, using the population models derived from the two studies in this thesis, in 
conjunction with Bayesian forecasting, a truly individualized immunosuppressant therapy 
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